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ABSTRACT 
Single or multiple administrations of the psychotomimetic drug, phencyclidine-
HCI (PCP), decreased striatal, cortical and accumbens, but not nigral, neuropeptide Y-
like immunoreactivity (NPYLI) levels at some time point(s) after administration. The 
effect of the noncompetitive NMDA receptor antagonist, MK-801, on striatal, cortical 
and accumbens NPYLI content was similar to PCP, suggesting that extrapyramidal and 
limbic NPY systems are modulated by glutamatergic activity through NMDA receptor 
mechanisms. Administration of the GABA-T inhibitors, amino-oxyacetic acid (AOAA) 
or gamma-vinyl-GABA (GVG) alone had no effect on striatal or cortical NPYLI levels; 
however, AOAA administration alone decreased accumbens NPYLI levels. Administra-
tion of AOAA or GVG prior to or concurrently with PCP treatment completely blocked 
PCP-induced changes in striatal and cortical NPYLI levels while accumbens NPYLI 
changes were attenuated. These data suggest that striatal, cortical and accumbens NPY 
systems are modulated by glutamatergic activity and that the interaction between these 
two transmitter systems is mediated, at least in part, by GABAergic mechanisms. The 
role of dopamine (DA) and several other transmitter or receptor systems in PCP-induced 
extrapyramidal and limbic NPYLI changes was also evaluated. Neither the dopamine D-
1 receptor, SCH 23390, nor the dopamine D-2 antagonist, sulpiride, by themselves 
altered cortical NPY systems but in combination they totally blocked the PCP-induced 
changes. In contrast, sulpiride alone significantly reduced striatal and accumbens NPYLI 
content and enhanced the PCP-induced decreases, while SCH 23390 alone had no effect 
on striatal and accumbens NPYLI levels but did attenuate PCP-induced effects. These 
data suggest that basal ganglia and limbic NPY systems are differentially modulated by 
NMDA and dopaminergic activity. Examination of the effects of multiple administrations 
of selective D-l and D-2 agonists and antagonists on striatal, nigral, accumbens, pallidal 
and cortical NPY systems indicated that within structures such as the caudate and nucleus 
accumbens there exists multiple distinct NPY systems which are uniquely influenced by 
DA receptors. Initial studies suggest that both GABA-A and -B receptors are involved 
in mediating the PCP-induced NPYLI changes, and that PCP causes both release of NPY 
from nerve terminals and increased peptide biosynthesis. 
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Neuropeptide Y (NPY) is a 36-amino acid peptide first isolated from porcine 
brain in 1982 (fatemoto, 1982). The peptide shares sequence homology with members 
of the pancreatic polypeptide family and contains both N- and C-terminaI tyrosine 
residues, hence the name neuropeptide Y (fatemoto, 1982; Tatemoto et aI., 1982). 
NPY, NPY message, and NPY binding sites are widely distributed in the centraI nervous 
system of various mammaIian species (Allen et aI., 1983; Gehlert et aI., 1987; Martel 
et aI., 1987). NPY meets many of the criteria for an interneuronaI neurotransmitter and 
has important effects in regulating neuroendocrine function, circadian rhythms, 
consummatory behavior, central autonomic control, memory processing (Heilig and 
Widerlov, 1990; Aakerlund et aI., 1990; Sheikh et aI., 1989; Hinson et aI., 1988; ) and 
in regulating contraction and relaxation of cerebral vessels (Abel and Han, 1989; Suzuki 
et aI., 1989). NPY co1ocalizes in specific brain areas with severaI transmitters including 
noradrenaIine, GABA and somatostatin, and interacts with neurotransmitter systems such 
as noradrenaIine, dopamine (DA) and GABA (Beal et aI., 1987; Kerkarian et aI., 1989; 
SaIin et aI., 1990; Massari et aI., 1988; Aoki and Pickel, 1989; Everitt et ai, 1984; 
Kubota et aI., 1988). 
2 
Altered tissue or cerebrospinal fluid (CSF) levels of neuropeptide Y -like 
immunoreactivity (NPYLI) have been implicated in several clinically important 
psychiatric disturbances, including depression, anxiety and schizophrenia (Heilig and 
Widerlov, 1990; Peters et al., 1990; Wahlestedt et al., 1989; Widerlov et al., 1987). 
In addition, several of the transmitter systems that are altered in these psychiatric 
illnesses are known to interact with NPY - containing neurons. 
Considerable interest exists about the role of NPY in several neurodegenerative 
diseases. In Huntington's chorea, the medium-sized aspiny striatal neurons containing 
NPY, somatostatin and N ADPH -diaphorase are selectively spared (Dawbarn et al., 1985; 
Ferrante et al., 1985; Chan-Paly, 1988; Beal et al., 1988). Observations that NPY- and 
somatostatin-sparing lesions can be produced by quinolinic acid but not other excitotoxins 
were reported but replication of these results has been equivocal (Bea1 et al., 1986; 
Boegman et al., 1987; Davies and Roberts, 1987). In Alzheimer's and Parkinson's 
diseases there appears to be a dissociation between the colocalized neuropeptides, NPY 
and somatostatin (Wahlestedt et al., 1989). Reports of dissociation between NPY and 
somatostatin and of NPYLI tissue degeneration indicate significant regional specificity, 
but studies are often conflicting (Heilig and Widerlov, 1990). However, the NPY-
containing cortical and hippocampal neurons in the Alzheimer's disease patient do 
undergo serious degenerative changes (Heilig and Widerlov, 1990; Wahlestedt et al., 
1989). In Parkinson's patients, no change in neocortical and hippocampal NPY 
concentration have been found despite significant reduction in somatostatin content (Allen 
et al., 1985). In addition, levels of NPY in frontal cortex, hippocampus and amygdala-
3 
/pyriform cortex are significantly elevated after acute kainic acid-induced seizures 
(Marksteiner et al., 1989) and in rats with decreased seizure thresholds due to pentyl-
enetetrazole kindling (Marksteiner and Sperk, 1988). 
We previously reported that dopamine-releasing drugs such as methamphetamine 
(METH), MDMA and cocaine significantly alter neurotensin-, dynorphin- and substance 
P-like immunoreactivity (LI) levels in a number of brain structures (Hanson et al., 1987 
a and b; Letter et al., 1987; Merchant et al., 1987). Subsequent studies indicated that 
NPYLI content is also affected by these dopamine-releasing drugs and is significantly 
altered in striatum, nucleus accumbens and frontal cortex (Midgley et al., 1989). These 
data suggest that NPYLI levels may be altered by dopaminergic action on specific post-
synaptic or presynaptic receptors. More recently, we identified that phencyclidine-HCl 
(PCP) alters striatal NPYLI levels (Midgley et al., 1990) in a manner similar to, but 
more profound than, that of MDMA and METH. The fact that PCP is a less potent DA 
releaser than METH suggested that some of PCP's actions on NPY-containing neurons 
may be mediated by systems other than dopamine (Contreras et al., 1987). Thus, 
Chapter 2 examines the effects of PCP administration on extrapyramidal NPY systems 
and identifies neurotransmitter systems that are important in mediating these PCP-induced 
NPYLI changes; Chapter 3 similarly examines the effects of PCP administration on 
limbic NPY systems; Chapter 4 evaluates the effects of administration of specific 
dopaminergic agonists and antagonists on NPY systems in discrete structures in the basal 
ganglia and limbic system; Chapter 5 examines the mechanisms by which these PCP-
induced NPYLI changes are occurring. 
4 
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CHAPTER 2 
CHARACTERIZATION OF PHENCYCLIDINE-INDUCED 
EFFECTS ON NEUROPEPTIDE Y SYSTEMS IN 
THE RAT CAUDATE-PUTAMEN 
Introduction 
NPY -like immunoreactive structures are found in high concentrations in many 
brain structures, including the basal ganglia (Beat et al., 1987; Martel et al., 1987). 
NPY-containing cells in the caudate-putamen, nucleus accumbens and frontal cortex are 
primarily aspiny intemeurons that form symmetrical junctions suggestive of inhibitory 
action (Aoki and Pickel, 1990; Massari et al.,1988; Vuillet et al., 1989). Afferent 
synapses with NPY perikarya and dendrites in the striatum are of both the symmetrical 
and asymmetrical type suggesting differential regulation of these neurons by other 
transmitter systems (Vuillet et al., 1989). In addition, axonal processes containing 
neuropeptide Y -like immunoreactivity are often found in proximity to cerebral vessels 
(Aoki and Pickel, 1990; Vuillet et al., 1989) and NPY alters contraction and relaxation 
of cerebral vessels in rat striatum (Suzuki et al., 1989) and in isolated rabbit cerebral 
arteries (Abel and Han, 1989). Furthermore, striatal NPY -containing neurons interact 
with several different neurotransmitter systems including dopamine and GABA (Aoki and 
Pickel, 1990; Beat et al., 1986; Kerkarian et al., 1988; Massari et al., 1988). 
9 
As mentioned in Chapter 1, alterations in tissue and cerebrospinal fluid levels of 
NPYLI have been implicated in several psychiatric disturbances (Wahlestedt et al., 
1989). Cerebrospinal fluid levels of NPY are significantly lower in depressed patients 
(Widerlov et al., 1987) and administration of antidepressants such as imipramine (a 
noradrenaline (NA) uptake blocker) and zimeldine (a 5-hydroxytryptamine (serotonin; 5-
HT) uptake blocker) increase the concentration of NPYLI in rat brain (Heilig and 
Widerlov, 1990). In addition, centrally administered NPY suppresses open-field and 
home cage activity in rat and produces anxiolytic-like effects in animal anxiety models 
(Heilig and Widerlov, 1990). Biochemical (Heilig and Widerlov, 1990; Tatsuoka et al., 
1987) and immunohistochemical data (Kerkarian et al., 1988; Lindefors et al., 1990) 
support the hypothesis that NPY and dopaminergic systems are interrelated and reciprocal 
regulation exists. This interaction with dopaminergic systems suggests that brain NPY 
parameters may be changed by conditions in which normal dopaminergic transmission 
is thought to be altered, such as schizophrenia. In support of this suggestion, Peters et 
al. (1990) reported increased NPYLI content in the CSF of drug-free schizophrenics; 
furthermore, withdrawal from haloperidol maintenance therapy was associated with 
significantly increased CSF levels of NPYLI. Reduced NPY concentrations have also 
been observed in the temporal cortex of a population of schizophrenic patients (Heilig 
and Widerlov, 1990). 
Phencyclidine HCI (PCP) is a common drug of abuse that can induce schizo-
phrenia-like psychotic behavior in users. PCP is known to interact with noradrenergic, 
cholinergic, serotonergic, GABAergic, and dopaminergic transmitter systems (Contreras 
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et al., 1987; Johnson and Jones, 1990; Junien and Leonard, 1989). We recently assessed 
levels of the rate-limiting enzyme in dopamine synthesis, tyrosine hydroxylase (TH), in 
striatal tissues 15 h after multiple PCP administrations and found a 20% decrease in TH 
activity (data not shown). In addition, PCP is a noncompetitive NMDA antagonist and 
binds with high affinity at the sigma-opioid receptor (Contreras et al., 1987; Johnson and 
Jones, 1990; Junien and Leonard, 1989). Other drugs of abuse that can cause symptoms 
of schizophrenia in abusers, such as amphetamine and cocaine, alter NPY parameters in 
the rat brain (Midgley et al., 1989; Tatsuoka et al., 1987; Tessel et al., 1985; Wahlestedt 
et al., 1991). In this study, we observed that PCP also profoundly alters NPY systems 
in the basal ganglia. We elucidated the nature of these PCP-induced changes and discuss 
their relevance to NPY regulation by other transmitter systems. 
Materials and Methods 
Animals and treatments 
Male Sprague-Dawley rats (180-270 g, Simonsen Laboratories, Gilroy, Ca) were 
maintained in a controlled environment with 12-h light/dark cycles and allowed free 
access to food and water. Drugs dissolved in 0.9 % saline included: phencyclidine HCI 
(pCP, National Institute on Drug Abuse, Rockville, MD); the serotonin toxin, DL-p-
chloroamphetamine HCI (PCA, Sigma Chemical Co., St. Louis, MO); the alphaJ-
adrenergic antagonist, prazosin H CI (pfizer Inc., Groton, CN); the alpha2-adrenergic 
antagonist, idazoxan HCI (Research Biochemicals Inc., Natick, MA); the dopamine D-l 
antagonist, SCH 23390 HCI (Research Biochemicals Inc., Natick, MA); the sigma 
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antagonist, rimcazole HCl (Burroughs Wellcome, Research Triangle Park, NC); the 
muscarinic cholinergic antagonist, atropine sulfate (Sigma Chemical Co., St. Louis, 
MO); the opioid antagonist, naloxone HCl (Research Biochemicals Inc., Natick, MA); 
the GABA-T (GABA transaminase) suicide inhibitor, gamma-vinyl-GABA (GVG, 
vigabatrin, MDL 71,754; Marion Merrell Dow Inc., Cincinnati, OH; Jung et al., 1977); 
the NMDA (N-methyl-D-aspartate) antagonist, MK-801 hydrogen maleate (dizocilpine, 
Research Biochemicals Inc., Natick, MA). Vehicles used for dissolving the following 
drugs were as follows: the dopamine D-2 antagonist, (+) sulpiride (Sigma Chemical 
Co., St. Louis, MO), in 2% lactate + 25% propylene glycol-saline; the indirect GABA-
T inhibitor, AOAA (Churchich, 1982) (aminooxyacetic acid hemi HCI, Sigma Chemical 
Co., St. Louis, MO), in saline neutralized with 20% of 1 N NaOH; the GABA antago-
nist, bicuculline (Sigma Chemical Co., St. Louis, MO), in saline acidified with 10% of 
0.1 N HC} and the sigma antagonist, BMY 14802 (Bristol-Meyers Squibb Co., 
Wallingford, CT), in 1 % lactate-saline. All drugs were administered intraperitoneally 
with the exceptions of PCP and the GABA antagonist, bicuculline, which were adminis-
tered subcutaneously. Rats administered PCA received two doses (10 mg/kg/dose) 24 
h apart, 1 week prior to challenge. This dosing regimen depletes striatal serotonin levels 
by 85 % (Smiley et al., 1990). Those administered the GABA-T suicide inhibitor, GVG, 
received 2 doses (1200 mg/kg/dose) 48 and 1 h prior to challenge. Drug doses, except 
for MK-801, were calculated for their free forms. Control animals received identical 
treatment regimens using vehicles only. 
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In acute experiments, animals received a single dose of PCP (15 mg/kg) and were 
sacrificed 12 h after treatment; or 6, 12 and 24 h after drug injection for recovery 
studies. For multiple dose experiments, animals received five doses of PCP (15 
mg/kg/dose), MK-801 (1 mg/kg/dose) or antagonist/agonist (unless otherwise specified 
above) 6 h apart and were sacrificed 18 h; 10, 18 or 34 h; or 12-15 h after the final 
dose for dose-effect, recovery and combination drug studies, respectfully. All antago-
nists were given 20 min prior to PCP administration. 
Dissections 
All animals were sacrificed by decapitation at the indicated times following 
treatment. Brains were rapidly removed and placed on ice, striata (caudate-putamen) were 
excised, and the remaining brain tissues immediately frozen on dry ice and stored at -
80°C until assayed for NPYLI. The substantia nigrae were identified according to the 
atlas of Konig and Klippel (1963), bilaterally dissected out from l.O-mm thick frozen 
coronal slices and stored at -80°C until assayed for NPYLI content. 
Neuropeptide Yantiserum 
The antiserum to NPY was prepared in our laboratory as described by Letter et 
al. (1987) using a modification of standard techniques (Hum and Chantler, 1970; Suess 
et al., 1986). Porcine NPY (1-36) was conjugated to thyroglobulin or hemocyanin with 
l-ethyl-3-(3-dimethylaminopropyl) carbodiimide as described by Skowsky and Fischer 
(1972). The mixture was incubated at room temperature for 24 h, after which an equal 
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volume of 1 M hydroxylamine was added to the reaction mixture. Following 4 or more 
hours of incubation, the conjugate was emulsified with complete or incomplete Freund's 
adjuvant and immediately injected intradermally into multiple sites on the backs of New 
Zealand White rabbits. Injections were administered once a week for 4 weeks and subse-
quently at 6-week intervals. The antiserum was harvested by heart puncture 10 days 
after the last booster. 
The resultant NPY antiserum reliably detects 8 pg of NPY when assayed at an 
antiserum dilution of 1:15,000. In the presence of l000-fold excess concentrations of 
related peptides, the NPY antiserum demonstrated less than 1 % cross-reactivity with 
peptide PPP and NPY fragment 18-36, less than 5% cross-reactivity with peptide PYY 
and less than 10% cross-reactivity with [Leu3l , Pro34]-NPY. Results are expressed as 
pg/mg protein of NPYLI. No significant cross-reactivity was observed between the NPY 
antiserum and unrelated peptides such as substance P and neurotensin. 
NPY radioimmunoassay 
The radioimmunoassay for NPYLI was performed according to a modification of 
the methods described by Hanson and Lovenberg (1980). Briefly, selected portions of 
brain were homogenized in 0.01 N HCI from which an aliquot was removed for protein 
analyses as described by Bradford (1976). The remaining homogenate was boiled for 10 
min, then centrifuged for I hat 3000 g. The supernatant was removed, lyophilized and 
stored at -800 C until assayed for NPYLI content. The samples were reconstituted in 
phosphate-buffered saline with gelatin plus 0.1 % Triton X-loo. Duplicate aliquots 
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(approximately 0.04% of total sample per aliquot) were mixed with NPY antiserum 
(1:15,000 final dilution) and incubated at 4°C for 4 days. 125I-Iabelled NPY (Amersham 
Co., Arlington Heights, IL) was added to the sample tubes and the reaction mixture was 
incubated at 4°C for another 2 days. Free and antibody bound 1251-labeUed NPY were 
separated by mixing the reactants with a dextran-coated charcoal slurry (Herbert et al., 
1965). Quantitation of NPYLI content was achieved by comparing bound to free 1251_ 
labelled NPY in each sample to a standard curve. 
Statistical analysis 
To facilitate comparisons between groups, results in all figures are shown as 
percentages of respective controls. Control and experimental groups of animals from 
each study were run in a single assay. The NPYLI control values are included in the 
figure legends. Bars represent the mean of treatment groups + S.E.M. Data were 
analyzed using a one factor ANOV A; if the F ratio was significant, a Fischer-PLSD 
(Protected Least Significant Difference) test was used to compare differences between the 
means of individual groups. Unless otherwise specified, differences were considered 
significant when the probability that they were zero was less than 5 %. 
Results 
Dose-effect response of striatal NPY systems to multiple 
PCP administrations 
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To evaluate the effects of PCP on striatal NPYLI content, rats were administered 
multiple doses (five doses, 6 h apart) of PCP at 5, 10 or 15 mg/kg/dose and sacrificed 
approximately 18 h after the final dose. PCP decreased striatal NPYLI levels in a dose-
dependent manner to 79, 55 and 35% of control, respectively (Figure 2.1). 
Recovery of striatal NPY systems after acute and mUltiple 
doses of pCP 
To assess the recovery of striatal NPY systems after acute PCP administration, a single 
injection of PCP (15 mg/kg) was given and rats were sacrificed 6, 12 or 24 h later. 
After acute treatment, striatal NPYLI levels were unchanged at 6 h, significantly 
decreased to 70% of control at 12 h, and recovered by 24 h (Figure 2.2 A). 
To assess the recovery of striatal NPY systems after multiple doses of PCP, rats 
received five injections of PCP (15 mg/kg/dose) at 6-h intervals, and were sacrificed 10, 
18,34 or 58 h after the final dose. Striatal NPYLI levels were decreased to 55,48, and 
56% after 10,18 and 34 h, and had returned to control by 58 h (Figure 2.2 B). 
Effects of single and multiple doses of pCP on NPYLI content 
in substantia nigra 
Because the substantia nigra is functionally related to the striatum, we assessed 
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Figure 2.1 . Effects of mul tiple administrations of various doses of PCP on 
striatal NPYLI content. Rats were given five doses of PCP (5, 10 or 15 
mg/kg/dose) at 6-h intervals and sacrificed 18 h after the fmal dose. Results are 
expressed as percent of control ± S.E.M. (n=6-8). The average value for control 
NPYLI levels was 328 ± 28 pg/mg protein. * p < 0.01 vs. control. 
150 
A • control C pcp (acute) 
---"S 
.!:: 






















6 hours 12 hours 24 hours 
150 
B • control 
g PCP (multiple) 
:g 
... 













10 hours 18 bours 34 hours 58 hours 
Figure 2.2. Effects of single and multiple PCP administrations on striatal NPYLI 
content. A. Rats were given a single dose of PCP (15mg/kg/dose) and sacrificed 
6, 12 or 24 h after injection. The average value for control NPYLI levels was 610 
± 65 pg/mg protein. * p < 0.05 vs. respective control. B. Rats were administered 
five doses of PCP (15 mg/kg/dose, s.c.) 6 h apart and sacrificed 10, 18, 34 or 58 h 
after the final dose. Average control value for NPYLI level was 555 ± 41 pg/mg 
protein. ** p < 0.01 vs. respective control. Results shown in both panels are 
expressed as percent of respective control ± S.E.M. (n=6). 
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the effects of single and multiple PCP administrations on nigral NPYLI content. Rats 
received a single (dose) or multiple doses (5 injections, 6 h apart) of PCP (15 
mg/kg/dose) and were sacrificed approximately 12-15 h after the single or final dose, to 
coincide with time points of maximal striatal effects. We observed no significant changes 
in nigral NPY levels with either acute or multiple administrations (data not shown). 
Role of monoamines in PCP-induced changes in striatal 
NPYLI content 
To investigate the relationship between monoamine systems and striatal NPY 
systems, 5-HT was depleted or selective monoaminergic antagonists were given alone or 
with PCP and NPYLI content was determined. 5-hydroxytryptamine was depleted with 
PCA (10 mg/kg/dose) as described in Materials and Methods. The dosing protocol for 
the antagonists and PCP was five doses administered with a 6-h interval between doses; 
animals were sacrificed approximately 10-15 h after the last dose. We observed that 
depletion of 5-HT alone with PCA did not significantly alter striatal NPYLI levels nor 
did it affect PCP-induced effects (Figure 2.3). Administration of idazoxan (0.125 
mg/kg/dose), a selective alpharadrenergic receptor antagonist, produced no effects alone 
or in combination with PCP; however, prazosin (0.5 mg/kg/dose), a selective alpha1-
adrenergic receptor antagonist, decreased striatal NPYLI levels alone (79 % ) and 
attenuated PCP's effect when given in combination (66 % vs. 44 %). Administration of 
the selective D-1 receptor antagonist, SCH 23390 (0.5 mg/kg/dose) had no effect by 
itself but significantly attenuated PCP's effects on striatal NPYLI content to 60% of 
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Figure 2.3. Effects of 5-HT depletion or selective monoamine receptor 
blockade alone and in combination with PCP on striatal NPYLI content. 
5-HT was depleted with PCA, or animals were given multiple doses of 
SCH 23390 (0.5 mg/kg/dose), sulpiride (80 mg/kg/dose), prazosin (0.5 mg! 
kg/dose) or idazoxan (0.125 mg/kg/dose) alone or in combination with PCP 
(15 mg/kg/dose) as described in Materials and Methods. Rats were sacrificed 
approximately 10-15 h after the final dose. Results are expressed as percent 
of control ± S.E.M. (n=6). Average control value for striatal NPYLI content 
was 463 ± 50 pg/mg protein. * p < 0.05 vs. control, ** p < 0.05 vs. PCP. 
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control (Figure 2.3). The selective D-2 antagonist, sulpiride (80 mg/kg/dose), signifi-
cantly decreased striatal NPYLI levels to 50% of control by itself but did not alter PCP-
induced striatal NPYLI changes. 
Effects of a cholinergic antagonist alone and in combination 
with PCP on striatal NPYLI content 
To investigate the relationship between the cholinergic system and striatal NPY 
systems, we administered the cholinergic antagonist, atropine (I mg/kg/dose), alone and 
in combination with PCP. Animals received five doses of atropine, PCP or a 
combination as previously described and were sacrificed approximately 15 h after the 
final dose. Atropine alone had no effect (107 ± 13 of control); coadministration of 
atropine did not significantly alter PCP-induced NPY changes (data not shown). 
Effects of sigma and nonselective opioid antagonists alone and 
in combination with PCP on striatal NPYLI content 
To evaluate the possible role of sigma and opioid receptors in regulating striatal 
NPY systems and in PCP-induced NPYLI changes, we administered selective antagonists 
in combination with PCP. Animals received multiple doses of PCP, antagonist or a 
combination as previously described and were sacrificed approximately 10-15 h after the 
final dose (Table 2.1). The putative sigma antagonist, rimcazole (12.5 mg/kg/dose), had 
no effect alone on striatal NPY levels and did not significantly alter PCP-induced 
changes, although a trend was suggested {two tailed p=.08 for combination vs. PCP 
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Table 2.1 
Effects of sigma and nonselective opioid receptor antagonists, alone and in combination 
with PCP, on striatal NPYLI content. 
Rats were administered five doses (6 h apart) of rimcazole (12.5 mg/kg/dose), 
BMY 14802 (35.0 mg/kg/dose) or naloxone (0.5 mg/kg/dose) alone and in combination 
with PCP (15 mg/kg/dose) and sacrificed 10-15 h after the final dose. Results represent 
combined data from three experiments expressed as percent of control ± S.E.M. (n= 
6-18). Average control values for striatal NPYLI content were 331 + 48 pg/mg protein. 
* p < 0.05 vs. vehicle without PCP. 
NPYLI (percent of control) 
Without PCP With PCP 
Vehicle 100 ± 5 * 47 + 4 
Rimcazole 94 ± 12 * 62 + 7 
BMY 14802 * 61 + 3 * 42 ± 12 
Naloxone 111 ± 4 * 49 ± 7 
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alone). In contrast, the putative sigma antagonist, BMY 14802 (35 mg/kg/dose), signifi-
cantly decreased NPYLI content to 61 % of control by itself and had little effect on PCP-
induced NPYLI changes. The opioid antagonist, naloxone (0.5 mg/kg/dose), had no 
effect on striatal NPYLI content by itself or when coadministered with PCP. 
Effects of GABA agonists or antagonists alone and in 
combination with PCP on striatal NPYLI content 
To investigate the role of GABA in the response of the striatal NPY system to 
PCP, a GABA antagonist and GABA-T inhibitors were administered alone and in 
combination with PCP (Figure 2.4 A and B). All animals were sacrificed approximately 
10-15 h after multiple dosing. The GABA antagonist, bicuculline (1 mg/kg/dose) 
produced a small but significant decrease in NPYLI levels when administered alone 
(79%) and had no effect on PCP-induced NPYLI alterations (Figure 2.4 A). The indirect 
GABA agonists, AOAA (15 mg/kg/dose) and GVG, had no effects by themselves, but 
both completely blocked PCP-induced changes in striatal NPYLI content (Figure 2.4 B). 
Effects of MK-801 and GABA agonists alone and in 
combination on striatal NPYLI content 
To determine if the PCP effect on striatal NPY systems was the result of NMDA 
receptor blockade, MK-801 (1 mg/kg/dose), a similar noncompetitive NMDA antagonist 
was administered in a manner like that described for PCP. Levels of striatal NPYLI 
declined to 71 % following MK-801 treatment. Coadministration of the GABA-T 
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Figure 2.4. Effects of GABA agonists and antagonist alone and with PCP on 
striatal NPYLI content. Rats were treated with multiple doses of bicuculline 
(1 mg/kg/dose; A), GVG (1200 mg/kg/dose; B) or AOAA (15 mg/kg/ 
dose; B) alone and in combination with PCP (15 mg/kg/dose). Rats were sacri-
ficed approximately 15 h after the last dose. Results are expressed as percent of 
control ± S.E.M. (n=6). Average control values for panels A and B NPYLI con-
tent were 220 ± 17 and 496 ± 37 pg/mg protein, respectively. * p < 0.05 vs. res-
pective controls, ** p < 0.05 vs. PCP. 
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inhibitors totally blocked the MK-801-induced effects in a manner similar to that 
observed with PCP (Figure 2.5). 
Discussion 
These studies demonstrate that PCP administration has profound effects on striatal 
NPY systems. Multiple doses of PCP reduced striatal NPYLI content in a dose-
dependent manner to as much as 35% of control (Figure 2.1). Significant declines 
occurred after both single and multiple PCP administrations; however, the effects of 
multiple administrations were more profound and of longer duration (Figure 2.2, A and 
B). These data demonstrate that PCP affects striatal NPY systems like other schizophre-
nia-inducing drugs of abuse, such as amphetamines and cocaine (Midgley et al., 1989; 
Tatsuoka et al., 1987; Tessel et al., 1985; Wahlestedt et al., 1991). Furthermore, the 
fact that acute administration of PCP produced significant decreases in striatal NPYLI 
content as soon as 12 h after administration suggests that the acute effects may be due 
in part to increased release and turnover of the peptide, although the possibility of altered 
synthesis cannot be excluded. No effects on nigra! NPYLI content were observed after 
either acute or multiple PCP treatments at the identified time points. The lack of a nigral 
NPY response suggests regional differences in regulation and function of basal ganglia 
NPY systems. Because monoamines participate in the function of the basal ganglia and 
PCP affects the activity of these pathways (Bowyer et al., 1984; Smith et al., 1977), the 
role of dopamine, norepinephrine and serotonin systems in the NPY response to PCP was 
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Figure 2.5. Effects of MK-801 administrations with and without GABA agonists 
on striatal NPYLI content. Rats were treated with GVG (see MateIials and 
Methods) or AOAA (15 mg/kg/dose, as previously described) alone and in com-
bination with MK-801 (1 mg/kg/dose). Rats were sacrificed approximately 15 h 
after the final dose. Results are expressed as percent of control ± S.E.M. (n=6). 
Average control value for NPYLI content was 596 ± 61 pg/mg protein. * p < 0.05 
vs. control, ** p < 0.05 vs. MK-801. 
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on striatal NPYLI but significantly attenuated the effects of PCP on striatal NPYLI levels 
(Figure 2.3). These data suggest that some of PCP's actions on NPY systems are 
mediated through the D-1 receptor. Other studies conducted in our laboratories have 
shown that methamphetamine produces a similar though less dramatic effect as PCP on 
striatal NPY levels, and its effects also are attenuated by D-1 receptor blockade (Midgley 
et al., 1989). The selective dopamine D-2 antagonist, sulpiride, significantly decreased 
striatal NPYLI content by itself, suggesting that D-2 receptors exert tonic activity over 
striatal NPY -containing neurons. These observations support the findings of Kerkarlan 
et al. (1988) that D-2 receptor blockade decreases the number of striatal NPY immunore-
active cells. However, D-2 receptor blockade had no effect on the PCP-induced changes 
in striatal NPYLI levels (Figure 2.3). 
Depletion of striatal 5-HT by PCA pretreatment had no significant effect on 
striatal NPYLI content either alone or in combination with PCP (Fig. 2.3). Furthermore, 
multiple administrations of the 5-HT uptake blocker, fluoxetine, failed to change striatal 
NPY levels alone and did not alter PCP-induced NPY alterations (data not shown). 
These data suggest that 5-HT receptor activation is not important in maintenance of basal 
NPYLI levels nor do serotonin systems contribute significantly to PCP-induced effects 
on NPYLI levels in the striatum. 
Interestingly, the alpha}-adrenergic antagonist, prazosin, produced a small but 
significant decrease in striatal NPYLI content by itself and significantly attenuated PCP's 
effects, whereas the alpha2-adrenergic antagonist, idazoxan, lacked an effect either alone 
or when coadministered with PCP (Figure 2.3). These results suggest that alpha! but not 
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alpha2 receptors play a small role in basal NPY regulation and contribute to the PCP-
induced striatal NPY response. However, the mechanism by which this occurs can not 
be determined from these data. 
Because of the reputed interaction of PCP (Contreras et al., 1987; Johnson and 
Jones, 1990; Junien and Leonard, 1989) and NPY (Roman et al., 1989) with the sigma 
receptor, and in view of data suggesting the involvement of sigma and other opioid 
receptors in regulation of nigrostriatal dopaminergic neurons (Iyengar et al., 1990; 
Manzanares et al., 1991), we evaluated the effects of two putative sigma antagonists, 
rimcazole and BMY 14802 (Ferris et al., 1986; Taylor and Dekleva, 1987), and the 
nonspecific opioid antagonist, naloxone. Interestingly, neither rimcazole or naloxone 
alone altered striatal NPY levels, whereas BMY 14802 significantly decreased striatal 
NPY content by itself (fable 2.1). The affinity of the BMY compound is over 20 times 
that of rimcazole for the the D-2 receptor (Largent et al., 1988). In view of these data 
and other reports that dopamine D-2 antagonism significantly reduces striatal NPY 
content (Kerkarian et al., 1988; Miyake et al., 1990; Midgley et al., 1989), it is possible 
that alteration of D-2 receptor activity is the mechanism by which BMY 14802 affects 
striatal NPY systems. However, since BMY 14802 has a relatively low affinity for D-2 
receptors and some affinity for receptors, such as the 5-HT2 and alpha1-adrenergic, other 
mechanisms may be involved as well (Largent et al., 1988). Neither of the two sigma 
antagonists, nor naloxone, altered the effects of PCP administration, although rimcazole 
showed a trend toward attenuation (Table 2.1). These data suggest that sigma and opioid 
systems are not the major components in PCP-induced alterations in striatal NPY content. 
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PCP has also been suggested to have cholinergic activity (Contreras et al., 1987; 
Johnson and Jones, 1990; Junien and Leonard, 1989). We therefore administered the 
cholinergic antagonist, atropine, alone and in combination with PCP. Atropine alone did 
not significantly alter striatal NPY levels and had no effect on PCP-induced alterations 
in striatal NPY, although there was considerable variability in the atropine alone group. 
These findings suggest that the cholinergic system is not a principal regulator of basal 
striatal NPY content and that PCP's effects on striatal NPY systems are not mediated by 
cholinergic activity. 
Vuillet et al. (1990) have shown that GABAergic neurons make synaptic contacts 
with NPY -containing neurons in the rat striatum. We therefore investigated the 
possibility that PCP-induced effects on striatal NPY content involve GABAergic systems. 
To test this hypothesis, we increased striatal GABA levels by administering inhibitors of 
the primary degradative enzyme for GABA, GABA-transaminase (GABA-T), or 
administered a selective GABA antagonist, bicuculline, at subconvulsive doses. As 
shown in Figure 2.4, administration of the indirect GABA agonists alone did not affect 
striatal NPY content, while administration of the GABA antagonist, bicuculline, signifi-
cantly reduced striatal NPYLI levels. The failure of bicuculline to completely mimick 
the effects of PCP was likely due to the dose utilized or its GABA-A receptor selectivity 
(i.e., perhaps the effect of PCP is both GABA-A- and -B-mediated). These data suggest 
that tonic GABAergic activity is necessary for maintenance of baseline striatal NPY 
levels. Furthermore, both indirect GABA agonists, AOAA and GVG, completely 
blocked PCP-induced changes in striatal NPY content, while bicuculline had little 
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additional effect on the large PCP-induced depletions. These findings suggest that the 
PCP effects on striatal NPY systems are mediated by GABA pathways. 
PCP has been identified as a potent noncompetitive antagonist at the NMDA 
receptor (Contreras et al., 1987; Johnson and Jones, 1990; Junien and Leonard, 1989). 
Stimulation of NMDA receptors releases GABA both from striatal neurons in primary 
culture (Weiss, 1990) and from striatal tissues in vivo (Young and Bradford, 1990). 
Furthermore, striatal NPY -containing neurons are influenced by corticostriatal and 
thalamostriatal projections (presumably glutamatergic)(Kerkarian et al., 1989; Vuillet et 
al., 1989). Because of these reports and our findings, we evaluated the effects of the 
selective NMDA antagonist, MK-801, alone and in combination with the GABA-T 
antagonists, AOAA and GVG (Figure 2.5) to compare with the PCP-induced effects. 
Treatment with MK -801 decreased striatal NPY content in a PCP-like manner, and the 
effect was similarly blocked by administration of the indirect GABA agonists, AOAA and 
GVG. These data confirm that striatal NPY-containing neurons are modulated by 
glutamatergic activity through NMDA receptors. In addition, the glutamatergic modula-
tion of these striatal NPY neurons is mediated by GABAergic systems. 
In summary, the results of this study suggest that striatal NPY pathways are 
regulated by NMDA receptors through GABAergic mechanisms. In addition, striatal 
NPY neurons also might be regulated by noradrenergic (through the alphacreceptor) and 
dopaminergic systems (through D-2 and D-1 receptors). PCP has a profound, reversible 
effect on striatal NPY systems that likely reflects the activity of this drug on NMDA and 
GABA systems; however, noradrenergic and dopaminergic factors may be involved as 
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well. The exact significance of the NPY changes in response to PCP is presently 
unclear, but these changes may contribute to locomotor, psychiatric or vascular responses 
to this drug. 
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CHAPTER 3 
DIFFERENTIAL REGULATION OF NEUROPEPTIDE Y 
SYSTEMS IN LIMBIC STRUCTURES OF THE RAT 
Introduction 
NPY -containing cells in litnbic structures such as the frontal cortex and nucleus 
accumbens are primarily aspiny interneurons that form symmetrical (inhibitory) junctions 
with other neurons; afferent synapses with cortical and accumbens NPY perikarya and 
dendrites are of both the symmetrical and asymmetrical type (Aoki and Pickel, 1989; 
Massari et al., 1988). NPY colocalizes with somatostatin in both the frontal cortex and 
nucleus accumbens (Beal et al., 1987); these neurons are also NADPH-diaphorase 
positive (Heilig and Widerlov, 1990). Most cortical NPYLI neurons are also positive 
for the GABA-synthesizing enzyme, glutamic acid decarboxylase (GAD) (Aoki and 
Pickel, 1988). NPYLI neurons in the nucleus accumbens receive direct GABAergic 
input (Massari et al., 1988), while direct contact between NPY -terminals and GABAergic 
somata or dendrites in the cortex has been observed (Aoki and Pickel, 1988). In 
addition, NPY neurons are associated with dopaminergic systems in several brain struc-
tures and reciprocal regulation may occur (Heilig and Widerlov, 1990; Kerkarian et al., 
1988). Specifically, dopamine stimulates NPY gene expression in the fronto-parietal 
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cortex (Lindefors et al., 1990) and 6-hydroxydopamine (6-0HDA) lesion of nigral 
dopaminergic neurons produces decreases in accumbens NPYLI (Salin et al., 1990). 
As mentioned in the previous chapter, PCP is a potent drug of abuse that 
produces agitation and a schizophrenia-like psychosis in abusers. PCP is a noncompeti-
tive NMDA antagonist and interacts with a number of neurotransmitters, including 
dopamine, GABA and serotonin systems (Contreras et al., 1987; Johnson and Jones, 
1990). In addition, PCP binds with high affinity to the sigma-opioid receptor (Contreras 
et al., 1987; Johnson and Jones, 1990). In Chapter 2, we reported that PCP administra-
tion significantly affects extrapyramidal NPY systems (Midgley et al., 1992). In this 
chapter, the profound effects ~f PCP on limbic NPY systems is described. These effects 
appear to be differentially regulated in the frontal cortex and nucleus accumbens. 
MaJerinls and Methods 
Animals and treatments 
Male Sprague-Dawley rats (180-270 g, Simonsen Laboratories, Gilroy, Ca) were 
maintained in a controlled environment as described in Chapter 2. Drugs dissolved in 
0.9% saline included: PCP (National Institute on Drug Abuse, Rockville, MD); the 
serotonin toxin, DL-p-chloroamphetamine HCI (pCA, Sigma Chemical Co., St. Louis, 
MO); the dopamine D-1 antagonist, SCH 23390 HCI (Research Biochemicals Inc., 
Natick, MA); the sigma antagonist, rimcazole HCI (Burroughs Wellcome, Research 
Triangle Park, NC); the GABA-T suicide inhibitor, gamma-vinyl-GABA (Jung et al., 
1977) (GVG, vigabatrin, MDL 71,754; Marion Merrell Dow Inc., Cincinnati, OH) and 
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the NMDA antagonist, MK-801 hydrogen maleate (dizocilpine, Research Biochemicals 
Inc., Natick, MA). Vehicles used for dissolving the following drugs were as follows: 
the dopamine D-2 antagonist, (+) sulpiride (Sigma Chemical Co., St. Louis, MO), in 
2% lactate + 25% propylene glycol-saline; the indirect GABA-T inhibitor, aminooxyac-
etic acid hemi HCL (Churchich, 1982) (AOAA; Sigma Chemical Co., St. Louis, MO), 
in saline neutralized with 20% 1 N NaOH. All drugs were administered intraperitoneally 
with the exception of PCP which was administered subcutaneously. PCA-treated rats 
received two doses (10 mg/kg/dose) 24 h apart, 1 week prior to PCP challenge. We 
have found this dosing regimen depletes striatal serotonin levels by 85 % (Smiley et al., 
1990). Animals administered GVG received two doses (1200 mg/kg/dose) 48 and 1 h 
prior to PCP challenge. Drug doses, except for MK-801, were calculated for their free 
forms. Control animals received identical treatment regimens using vehicles only. 
In acute recovery studies, animals received a single dose of PCP (15 mg/kg) and 
were sacrificed 6, 12 and 24 h after drug injection. For mUltiple dose experiments, 
animals received five doses of PCP (15 mg/kg/dose), MK-801 (1 mg/kg/dose) or 
antagonist/agonist (unless otherwise specified above) 6 h apart and were sacrificed at 10, 
18, 34 or 58 h after the final dose for recovery studies and 12-15 h after the final dose 
for combination drug studies. All antagonists and agonists were given 20 min prior to 
PCP administration, unless otherwise specified. 
All animals were sacrificed by decapitation at the indicated times following 
treatment. Brains were rapidly removed and placed on ice, frontal cortices were excised, 
and the remaining brain tissues immediately frozen on dry ice and stored at -80°C until 
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assayed for NPYLI. The nucleus accumbens was identified according to the atlas of 
Konig and Klippel (1963), bilaterally dissected out from l.O-mm thick frozen coronal 
slices and stored at -80°C until assayed for NPYLI content. 
Neuropeptide Y radioimmunoassay 
The antiserum to NPY was prepared in our laboratory as described in Chapter 2. 
The resultant NPY antiserum reliably detects 8 pg of NPY when assayed at an antiserum 
dilution of 1: 15,000. Results of cross reactivity assays and a description of the 
radioimmunoassay for NPYLI were presented in the previous chapter. Results are 
expressed as pg/mg protein of NPYLI. 
To facilitate comparisons between groups, results in all figures are shown as 
percentages of respective controls. The NPYLI control values are included in the figure 
legends. Bars represent the mean of treatment groups + S.E.M. Data were analyzed 
using a one factor ANOV A; if the F ratio was significant, a Fischer-PLSD (Protected 
Least Significant Difference) test was used to compare differences between the means of 
individual groups. Unless otherwise specified, differences were considered significant 
when the probability that they were zero was less than 5 % . 
Results 
Effects of acute and multiple doses of pCP on cortical and 
accumbens NPY systems after varying times 
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The time course for effects of acute and multiple doses of PCP on cortical and 
accumbens NPY systems is described in Figures 3.1 and 3.2. To evaluate the response 
of cortical and accumbens NPY systems to acute PCP administration, a single dose of 
PCP (15 mg/kg) was administered and rats were sacrificed 6, 12 or 24 h after injection. 
After acute treatment, cortical NPYLI levels were unchanged at 6 h, decreased to 74% 
of control at 12 h, and returned to control by 24 h (Figure 3.1 A). In contrast, 
accumbens NPYLI levels were significantly decreased to 76% of control at 6 h, and 
recovered by 12 h (Figure 3.2 A). 
To evaluate the response of cortical and accumbens NPY systems to multiple 
doses of PCP, animals received five injections of PCP (15 mg/kg/dose) at 6-h intervals, 
and were sacrificed 10, 18, 34 or 58 h after the last dose. Cortical NPYLI levels were 
decreased to 52% and 62% after 10 and 18 h, respectively, and returned to control by 
34 h (Figure 3.1 B). NPYLI levels in the nucleus accumbens were decreased to 49, 44 
and 68% after 10, 18 and 34 h, respectively, and recovered by 58 h (Figure 3.2 B). 
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Figure 3.1. Effects of acute and multiple administrations of PCP on cortical NPYLI 
content. A. Rats received a single dose of PCP (15 mg/kg) and were sacrificed 6, 
12 or 24 h after injection. B. Rats were administered five doses of PCP (15 mg/kg/ 
dose) 6 h apart and sacrificed 10, 18, 34 or 58 h after the final dose. Results shown 
in both panels are expressed as percent of respective control ± S.E.M. (n=5-6). The 
average value for control NPYLI levels was 598 ± 49 pg/mg protein. * p < 0.05 vs. 
respective control. 
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Figure 3.2. Effects of acute and multiple administrations of PCP on NPYLI 
content in the nucleus accumbens. Rats were treated with one (A) or multiple (B) 
doses of PCP as described for Figure 3.1. Results in both panels are expressed as 
percent of respective control ± S.E.M. (n=6). The average value for control 
NPYLI levels was 6842 ± 273 pg/mg protein. * p < 0.05 vs. respective control. 
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Effects of 5-hydroxytryptamine depletion and sigma, dopamine 
D-J and D-2 receptor blockade alone and in combination 
with PCP on cortical and accumbens NPY systems 
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To assess the role of selected monoamine pathways in regulating cortical and 
accumbens NPY systems and PCP-induced changes in NPYLI content, 5-hydroxytrypta-
mine was depleted or selective dopaminergic antagonists were administered alone and in 
combination with PCP (Figures 3.3 and 3.4). In addition, the possible role of sigma 
receptors in the regulation of these systems and in the PCP-induced changes was 
evaluated by cotreatment with the selective sigma antagonist, rimcazole. 5-hydroxytryp-
tamine content was depleted with PCA (10 mg/kg/dose) pretreatment as described in 
Materials and Methods. Animals received five doses of PCP (15 mg/kg/dose), 
antagonists or combinations at 6-h intervals and were sacrificed approximately 10-15 h 
after the final dose. All antagonists were administered 20 min before each injection of 
PCP. Neither the selective D-l antagonist, SCH 23390 (0.5 mg/kg/dose), the selective 
D-2 antagonist, sulpiride (80 mg/kg/dose), 5-HT depletion or the putative sigma 
antagonist, rimcazole (12.5 mg/kg/dose) alone had any effect on cortical NPYLI content 
(Figure 3.3 A). In contrast, accumbens NPYLI content was significantly decreased to 
73 % and 85 % of control by sulpiride and PCA, respectively (Figure 3.4 A). The 
selective D-l antagonist, SCH 23390, attenuated PCP-induced NPYLI changes in the 
cortex and accumbens (from 73% and 54% to 92% and 71 %, respectively) (Figures 3.3 
A and 3.4 A). The effects of the selective D-2 antagonist, sulpiride, appeared to be 
additive with PCP-induced NPYLI decreases in the accumbens (Figure 3.4 A). 
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Figure 3.3. Effects of 5-HT depletion or selective sigma, dopamine D-l or 
D-2 receptor blockade alone and in combination with PCP on cortical NPYLI 
content. A. 5-HT was depleted with PCA, or animals received multiple doses 
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of SCH 23390 (SCH; 0.5 mglkg/dose), sulpiride (Sulp; 80 mg/kg/dose) or rimcazole 
(Rimc; 12.5 mg/kg/dose) alone and in combination with PCP (15 mg/kg/dose) as 
described in Materials and Methods. Average control value for NPYLI levels was 
948 ± 61 pg/mg protein. B. Rats were administered multiple doses of SCH 23390 
(0.5 mg/kg/dose), sulpiride (80 mg/kg/dose) or a combination of the two with or 
without PCP (15 mg/kg/dose ). Average control value for NPYLI levels was 666 ± 
52 pg/mg protein. Rats in both experiments were sacrificed approximately 10-15 h 
after the final dose. Results are expressed as percent of control ± S.E.M. (n=6). 
*p < 0.05 vs. control; **p < 0.05 vs. PCP. 
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Figure 3.4 Effects of 5-HT depletion or selective sigma, dopamine D-1 or D-2 
receptor blockade alone and in combination with PCP on NPYLI content in the 
nucleus accumbens. Rats were treated as described for Figure 3.3. Average control 
value for NPYLI levels in Figure 3.4 A was 2695 ± 107 pg/mg protein. Average 
control value for NPYLI levels in Figure 3.4 B was 1916 ± 171 pg/mg protein. 
Results are expressed as percent of control ± S.E.M. (n=6). * p < 0.05 vs. control; 
** p < 0.05 vs. PCP. 
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However, sulpiride did not enhance PCP-induced changes in the cortex (Figure 3.3 A). 
Neither PCA or rimcazole altered PCP-induced changes in either structure (Figures 3.3 
A and 3.4 A). 
To evaluate further the differences in dopaminergic regulation of cortical and 
accumbens NPY systems and the role of DA pathways in PCP-induced changes in 
NPYLI content, we administered SCH 23390, sulpiride, and a combination of the two 
drugs alone and with PCP (Figures 3.3 Band 3.4 B). Treatment paradigms were similar 
to those used for corresponding A panels. Coadministration of SCH 23390 plus sulpiride 
had no effect on NPYLI content in the frontal cortex but completely blocked PCP-
induced decreases (from 64% to 125% of control) in cortical NPYLI levels (Figure 3.3 
B). In contrast, coadministration of SCH 23390 and sulpiride decreased accumbens 
NPYLI content (to 73 % of control) in a manner similar to sulpiride alone (68 % of 
control) and did not significantly alter PCP-induced NPYLI decreases (53% of control) 
(Figure 3.4 B). 
Effects of multiple doses of MK-80J and pCP with and without 
GABA -enhancing drugs on NPYLI content in the frontal 
conex and nucleus accumbens 
To investigate the role of GABA in regulating cortical and accumbens NPY and 
the response to PCP treatment, we administered selective GABA-T inhibitors alone and 
in combination with PCP (15 mg/kg/dose)(Figures 3.5 and 3.6). In addition, to 
determine if the effects of PCP on NPYLI content in these structures were the result of 
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Figure 3.5 Effects of multiple MK-801 (MK) or PCP administrations with and with-
out GABA agonists on cortical NPYLI content. Rats were treated with GVG (see 
Materials and Methods) or AOAA (15 mg/kg/dose) alone and in combination with 
MK-801 (1 mg/kg/dose) or PCP (15 mg/kg/dose). Rats were sacrificed approximate-
ly 15 h after the final dose. Results are expressed as percent of control ± S.E.M. 
(n=4- 9). Average control value for NPYLI content was 492 ± 30 pg/mg protein. 
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Figure 3.6. Effects of multiple MK-801 (MK) or PCP administrations with and 
without GABA agonists on NPYLI content in the nucleus accumbens. Rats were 
treated as described for Figure 3.5. Results are expressed as percent of control ± 
S.E.M. (n=5-9). Average control value for NPYLI content was 2937 ± 255 pg/mg 
protein. * p < 0.05 VS. control; ** p < 0.05 VS. PCP; § p < 0.05 vs. MK-801. 
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NMDA receptor blockade, MK-801 (1 mg/kg/dose), a PCP-like noncompetitive NMDA 
antagonist, was administered in the same manner as PCP (Figures 3.5 and 3.6). Animals 
received five doses of PCP, MK-801 or AOAA (15 mg/kg/dose) at 6-h intervals and 
were sacrificed approximately 10-15 h after the final dose. GVG was administered as 
described in Materials and Methods. PCP alone decreased cortical and accumbens 
NPYLI content to 57% and 42 % of control, respectively; MK-801 alone decreased 
cortical and accumbens NPYLI levels in a PCP-like manner to 67% of control in both 
structures (Figures 3.5 and 3.6). Higher doses of MK-801 produced quantitatively 
similar changes to this dose of PCP (data not shown), but were not used due to potential 
lack of selectivity. The indirect GABA agonists, GVG and AOAA, had no effect by 
themselves on cortical NPYLI levels; AOAA alone decreased (to 71 % of control) 
accumbens NPYLI content. Coadministration of either GABA-T inhibitor completely 
blocked both the PCP and MK-801-induced cortical decrease in NPYLI content. 
However, the effect of enhancing GABA activity on PCP or MK-801-induced changes 
in accumbens NPY systems is more difficult to interpret since at least one of the GABA-
T inhibitors (AOAA) alone appeared to have an effect on accumbens NPYLI levels. 
GVG and AOAA attenuated accumbens PCP-induced decreases from 42 % to 60% and 
58%, respectively. GVG significantly attenuated MK-801-induced accumbens effects 
from 67% to 86%; the trend towards attenuation by AOAA from 67% to 78% did not 
reach statistical significance. It is not clear if enhancing GABA activity totally blocked 
the PCP and MK-801 effects on accumbens NPYLI levels because AOAA plus PCP or 
MK-801 was not different from AOAA alone nor was GVG plus MK-801 different from 
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ava alone. ava plus PCP was somewhat different in that the combination effect was 
intermediate between either drug alone. Even so, from these data it is clear that GABA 
systems are involved in the response of limbic NPY pathways to the effects of PCP and 
MK-801. 
Discussion 
Acute and multiple dose experiments revealed that PCP administration has 
profound effects on NPY systems in the frontal cortex and nucleus accumbens. The 
present data also suggest that cortical and accumbens NPY systems are differentially 
regulated. The disparate time courses for PCP-induced NPYLI decreases in these two 
structures could reflect differences in drug distribution, regulation by other transmitter 
systems, release and turnover of the peptide, or peptide synthesis. Additional 
experiments must be conducted to determine which of these possibilities are responsible 
for the differences. 
PCP alters brain dopaminergic and serotonergic parameters and binds to sigma 
opioid receptors (Contreras et al., 1987; Johnson and Jones, 1990). Central NPY 
systems interact with dopaminergic and serotonergic systems as well as with sigma 
receptors (Heilig et al., 1990; Roman et al., 1989; Schlicker et al., 1991). Thus, in 
order to determine if any of these systems are involved in mediating the PCP effects on 
limbic NPY pathways, we depleted 5-HT with PCA or administered selective 
dopaminergic or sigma antagonists alone and in combination with PCP (Figures 3.3 and 
3.4). Interestingly, there were significant differences in the responses of cortical and 
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accumbens NPY systems to the selective dopaminergic antagonists alone and in 
combination with PCP, supporting the hypothesis of differential regulation. The selective 
D-l antagonist, SCH 23390, had no significant effect on either cortical or accumbens 
NPYLI levels. However, in both structures coadministration of SCH 23390 with PCP 
attenuated PCP-induced effects (Figures 3.3 A and 3.4 A), suggesting that the PCP-
induced decreases in both structures are mediated in part through D-l receptors. The 
selective D-2 antagonist, sulpiride, alone significantly decreased accumbens NPYLI 
content but had no effect on cortical NPYLI levels, indicating that accumbens, but not 
cortical, D-2 receptors may be important in maintaining basal NPY levels. Coadminis-
tration of sulpiride with PCP had no significant effect on cortical PCP-induced changes, 
yet enhanced PCP-induced decreases in accumbens NPYLI content (Figures 3.3 A and 
3.4 A). This enhancement of PCP's effects in the accumbens could be due to the 
summation of separate or similar mechanisms: this study cannot distinguish between 
these two possibilities. In additional experiments, we administered SCH 23390 and 
sulpiride together with PCP. Coadministration of SCH 23390 and sulpiride had no 
significant effect on cortical NPYLI levels and decreased accumbens NPYLI levels like 
sulpiride alone. Significantly, administration of the D-l and D-2 antagonists together 
completely blocked PCP-induced cortical NPYLI changes but had no effect on PCP-
induced NPYLI decreases in the nucleus accumbens. These data suggest that the 
dopaminergic system through both D-l and D-2 receptors plays an important role in 
mediating PCP-induced changes in the cortex. In contrast, only the D-l receptor has a 
partial role in mediating PCP-induced decreases in accumbens NPYLI levels. 
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Collectively, these dopamine antagonist data indicate that there are important differences 
in the regulation of cortical and accumbens NPY systems by the dopaminergic system. 
Depletion of 5-HT with PCA produced no change in cortical NPYLI content and 
a small but significant decrease (15%) in accumbens NPYLI level. This decrease could 
reflect direct or indirect interactions between accumbens NPY and serotonin systems. 
However, in neither structure did PCA pretreatment alter PCP-induced changes, 
suggesting that 5-HT systems do not play an important role in mediating PCP-induced 
NPYLI decreases in the cortex and accumbens (Figure 3.3 and 3.4). 
Administration of the selective sigma antagonist, rimcazole, had no effect on 
NPYLI content alone nor did it alter the PCP-induced NPYLI changes in either structure 
(Figures 3.3 A and 3.4 A). These data suggest that sigma receptor activity has little 
effect on cortical and accumbens NPY systems nor is it involved in mediating PCP-
induced changes in limbic NPY pathways. 
In 1988, Pin et ale demonstrated that NMDA-evoked GABA release from primary 
cultures of striatal neurons could be blocked in a competitive or noncompetitive manner 
by DL-2-amino-5-phosphovalerate (APV) or PCP, respectively. In addition, Young and 
Bradford (1990) reported that NMDA releases GABA from rat striatum in vivo. We 
recently observed that administration of both PCP and the more selective noncompetitive 
NMDA antagonist, MK-801, significantly decreased striatal NPYLI levels; moreover, 
these changes were completely blocked by coadminstration of inhibitors of the primary 
degradative enzyme for GABA, GABA-transaminase (GABA-T) (Midgley et al., 1992). 
Because of the NMDA effects of PCP and the fact that both cortical and accumbens NPY 
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systems interact with GABAergic systems (Massari et al., 1988; Aoki and Pickel, 1989), 
we administered the GABA-T inhibitors, AOAA and GVG, alone or in combination with 
PCP and MK-801 (Figure 3.5 and 3.6). Administration of GVG or AOAA alone had 
no effect on cortical NPYLI content. In the nucleus accumbens, GVG had no significant 
effect on NPYLI levels whereas AOAA decreased NPYLI content to 71 % of control. 
This difference is possibly due to the distinct mechanisms of the two drugs. GVG is a 
selective suicide inhibitor of GABA-T whereas AOAA inhibits binding of the cofactor 
(pyridoxal phosphate) to GABA-T, and is thus less selective (Jung et al., 1977; 
Churchich, 1982). Multiple administrations ofMK-801 decreased NPYLI content in both 
limbic structures in a manner similar to PCP, confirming that cortical and accumbens 
NPY -containing neurons are modulated by glutamatergic activity through NMDA 
receptors. Coadministration of GVG and AOAA completely blocked both PCP- and MK-
801-induced cortical NPYLI changes, suggesting that glutamatergic modulation of 
cortical NPY -containing neurons is mediated primarily by GABAergic systems (Figure 
3.5). The results in the nucleus accumbens are more difficult to explain. In this tissue, 
GVG appeared to attenuate only PCP- and MK-801-induced changes. AOAA 
significantly attenuated the PCP-induced decrease in accumbens NPYLI levels but not 
MK-801 induced changes; this lack of attenuation of MK-801-induced effects was likely 
due to the decrease in NPYLI content produced by AOAA alone and to the less dramatic 
decreases in NPYLI levels produced by this dose of MK -801. These data suggest that 
glutamatergic modulation of accumbens NPY -containing neurons is only partially 
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mediated by GABAergic systems, and that differential regulation of cortical and 
accumbens NPY systems by GABAergic systems exists. 
In summary, the results of this study indicate that PCP has a profound, reversible 
effect on cortical NPY systems which is likely due to the effects of this drug on NMDA, 
GABAergic and dopaminergic systems. Specifically, these data demonstrate that 
regulation of cortical NPY pathways by NMDA receptors occurs through GABAergic 
mechanisms. The complete blockade of PCP-induced cortical NPYLI decreases by 
coadministration of dopamine D-1 and D-2 receptor antagonists suggests that dopa-
minergic receptor activation is also important in mediating these PCP-induced changes. 
These studies also suggest that accumbens NPY systems are profoundly and reversibly 
affected by PCP administration, likely due to the effects of this drug on NMDA systems. 
In contrast to the cortex, GABAergic mechanisms appear to mediate only partially 
NMDA receptor regulation of accumbens NPY systems. In addition, accumbens NPY 
systems seem to be tonically regulated by D-2 receptor activity, and PCP-induced 
accumbens NPYLI changes partially mediated through the D-1 receptor. Further studies 
must be performed to clarify the relationship between NMDA, dopaminergic and 
GABAergic systems in the regulation of NPY -containing neurons in the limbic system. 
The significance of limbic NPY alterations in response to a psychotomimetic drug 
such as PCP cannot presently be ascertained. Decreases in NPYLI levels can be caused 
by (1) an increase in the neuronal release of NPY, resulting in increased metabolism by 
degrading peptidases, (2) a decrease in synthesis or, (3) a combination of both (1) and 
(2). Additional research is necessary to identify the mechanisms involved. Because of 
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the possible association of NPY with psychiatric disorders (Widerlov et al., 1989), 
changes in NPY systems by PCP may contribute to the psychiatric manifestations of this 
drug. Furthermore, the differential regulation and modulation of these limbic NPY 
systems could suggest problems or solutions in treatment strategies for psychiatric 
disorders in which NPY systems are thought to be involved. 
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CHAPTER 4 
DYNAMIC DOPAMINERGIC REGULATION OF 
NEUROPEPTIDE Y SYSTEMS IN DISCRETE 
STRIATAL AND ACCUMBENS REGIONS 
Introduction 
Numerous studies support the hypothesis that neuropeptide Y and dopaminergic 
(DA) systems are interrelated and that reciprocal regulation occurs. Centrallyadminis-
tered NPY produces a dose-related increase in the levels of DA and its metabolite, 
DOPAC, in striatum, frontal and parietal cortex, hypothalamus and brain stem in the rat 
(Heilig and Widerlov, 1990). Immunohistochemical data indicate that NPY -immunoreac-
tive (NPYIR) neurons receive synaptic input from tyrosine hydroxylase-immunoreactive 
axon terminals in the rat neostriatum (Kubota et al., 1988; Vuillet et al, 1989). A 
unilateral 6-hydroxydopamine (6-0HDA) lesion of the nigrostriatal dopamine pathway 
markedly increases NPYLI in striatal perikarya in the ipsilateral deafferented side, which 
can be reversed by administration of the direct-acting dopamine agonist, apomorphine. 
Interestingly, administration of the nonselective dopamine receptor antagonist, 
haloperidol, or the dopamine synthesis inhibitor, alpha-methyl-p-tyrosine, produces a 
decrease in the number and labeling intensity of striatal NPY like-immunoreactive cells 
(Kerkarian et al., 1988). Salin et al. (1990) showed that unilateral 6-0HDA lesions of 
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the nigrostriatal dopaminergic pathway result in bilateral decreases in accumbens NPY 
neuron density which are more marked on the contralateral than ipsilateral side. This 
effect is completely reversed ipsilaterally and partially reversed on the contralateral side 
by apomorphine administration. Lindefors et al. (1990) showed that unilateral6-0HDA 
lesions increase NPY and somatostatin mRNA in the caudate-putamen and decrease NPY 
and somatostatin mRNA in the fronto-parietal cortex, suggesting tonic inhibition and 
stimulation, respectively, of NPY -containing neurons by DA in these structures. These 
data indicate an important, albeit complex, role for dopamine in the regulation of 
telencephalic NPY -containing neurons. 
To understand further the role of DA in the regulation of striatal NPY -containing 
neurons, several investigators have utilized selective D-1 and D-2 receptor antagonists 
and agonists. Immunohistochemical data indicate that the selective D-2 antagonist, 
sulpiride, decreases, while the selective D-l antagonist, SCH 23390, produces slight 
increases in the number of striatal NPYLI cells (Kerkerian et al., 1988). These data 
suggest an opposite role for D-1 and D-2 receptor subtypes in dopaminergic control of 
rat striatal NPY neurons. We previously reported that multiple dosing with either the 
selective D-2 antagonist, sulpiride, or the D-2 agonist, quinpirole, significantly decreases 
rat striatal NPYLI content (Midgley et al, 1989). We observed no significant differences 
in striatal NPYLI content after similar administrations of either the selective D-l 
antagonist, SCH 23390, or the D-1 agonist, SKF 38393. Engber et al. (1992) reported 
that intermittent quinpirole administration decreases, while continuous quinpirole 
administration increases rat striatal NPYLI levels. In addition, they observed that both 
59 
intermittent and continuous administration of the D-l agonist, SKF 38393, significantly 
reduces striatal NPYLI content. These findings suggest that striatal NPY systems are 
regulated by selective dopaminergic activity at specific postsynaptic or presynaptic 
receptors. In this chapter we elucidate further the role of DA in modulating NPY 
systems in the rat basal ganglia and limbic system, and the response of these NPY 
systems to stimulation or blockade of D-l or D-2 receptors. We observed significant 
differences in dopaminergic regulation of NPY systems in discrete structures within 
extrapyramidal and limbic systems. 
Materials and Methods 
Animals and treatments 
Male Sprague-Dawley rats (180-270 g, Simonsen Laboratories, Gilroy, CAl were 
maintained in a temperature-controlled environment as previously described. The 
dopamine D-l antagonist, SCH 23390 (Research Biochemicals Inc., Natick, MA), was 
dissolved in 0.9% saline. The dopamine D-l agonist, SKF 38393 (Research Bio-
chemicals, Inc.), and the dopamine D-2 antagonist, (+) sulpiride (Sigma Chemical Co., 
St. Louis, MO), were dissolved in 2 % lactate + 25 % propylene glycol-saline; the 
dopamine D-2 agonist, quinpirole (Lilly 171555; Research Biochemicals Inc.), was 
dissolved in 1 % lactate-saline. Animals received five doses of SKF 38393 (20 
mg/kg/dose, i.p.), quinpirole (5 mg/kg/dose, Lp.), SCH 23390 (0.5 mg/kg/dose, Lp.) 
or sulpiride (80 mg/kg/dose, Lp.) at 6-h intervals and were sacrificed 18 h (single time 
point study) or 3, 12 and 48 h (recovery study) after the final dose. 
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Dissections 
All animals were sacrificed by decapitation at the indicated times following 
treatment. For whole structure analyses, brains were rapidly removed and placed on ice, 
frontal cortex and caudate-putamen excised, and the remaining brain tissues immediately 
frozen on dry ice and stored at -80°C until assayed for NPYLI. Nucleus accumbens and 
substantia nigrae were identified according to the atlas of Konig and Klippel (1963), 
bilaterally dissected out from 1.0-mm thick frozen coronal slices and stored at -8a> C 
until assayed for NPYLI content. For regional studies, brains were rapidly removed, 
frozen on dry ice and stored at -80° C until dissection. The caudate-putamen was 
dissected into very anterior caudate (V AC), medial anterior caudate (MAC), lateral 
anterior caudate (LAC), medial posterior caudate (MPC), lateral posterior caudate (LPC) 
and very posterior caudate (VPC) as represented in Figure 4.1 A-D. Nucleus accumbens 
was dissected into anterior (ANA) and posterior (PNA) regions as identified in Figure 
4.1 A and B. Globus pallidus was dissected according to Figure 4.1 D. Tissue slices 
were I-mm thick and dissected posteriorly from the following locations: 2.5 mm anterior 
to bregma to remove the VAC and ANA, 1.5 mm anterior to bregma for removal of 
MAC, LAC and PNA, 0.5 mm anterior to bregma to remove MPC and LPC, and 0.5 
mm posterior to bregma for removal of VPC and GP. All tissues were dissected on ice 
and stored at -80° C until assayed for NPYLI content. 
Determination of regional NPYLI content 
Preparation of the antiserum to NPY and the radioimmunoassay for NPYLI are 
A. 
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378 ± 23 
3206 ± 238 
(MAC) 
(ANA) 
4796 ± 444 
(PNA) 
D. 
642 ± 3 
(LPC) 294 ± 16 
(VPC) 
785 ± 29 
(MPC) 3748 ± 298 
(GP) 
Figure 4.1. Description of regional dissections of caudate, nucleus accum-
bens and globus pallidus and their respective control levels of NPYLI (pg/mg 
protein). A. Very anterior caudate (VAC) and anterior nucleus accumbens 
(ANA), 2.5 mm anterior to bregma. B. Medial anterior caudate (MAC), 
lateral anterior caudate (LAC) and posterior nucleus accumbens (PNA), 
1.5 mm anterior to bregma. C. Medial posterior caudate (MPC) and lateral 
posterior caudate (LPC), 0.5 mm anterior to bregma. D. Very posterior 
caudate (VPC) and globus pallidus (GP), 0.5 mm posterior to bregma. 
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described in Chapter 2. Results are expressed as pg/mg protein of NPYLI. 
To facilitate comparisons between groups, results in all figures are shown as 
percentages of respective controls. The NPYLI control values are included in the figure 
legends. Bars represent the mean of treatment groups + S.E.M. Data were analyzed 
using a one-factor ANOVA; if the F ratio was significant, a Fischer-PLSD (Protected 
Least Significant Difference) test was used to compare differences between the means of 
individual groups. Unless otherwise specified, differences were considered significant 
when the probability that they were zero was less than 5 % . 
Results 
Effects of multiple dose DA agonist and antagonist treatments 
on NPYLI content in striatum, substantia nigra, nucleus 
accumbens, and frontal cortex. 
To investigate the importance of dopaminergic activity in regulating extrapyrami-
dal and limbic NPY systems, we administered multiple doses of the selective D-l 
agonist, SKF 38393, the D-2 agonist, quinpirole, the D-l antagonist, SCH 23390, or the 
D-2 antagonist, sulpiride, at 6-h intervals and sacrificed the rats 18 h after the final dose 
(Table 4.1). Neither the dopamine D-l agonist (SKF 38393) nor the D-l antagonist 
(SCH 23390) produced any significant effects on striatal NPYLI content. However, both 
quinpirole and sulpiride decreased striatal NPYLI levels (69 and 59 % of control, 
respectively). There were no significant effects on nigral NPYLI systems with any of 
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Table 4.1 
Effect of D-J and D-2 stimulation and blockade on NPYLI content in the striatum, 
substantia nigra, nucleus accumbens and frontal conex. 
Animals were administered five doses of SKF 38393 (20 mg/kg/dose), quinpirole 
(5 mg/kg/dose), SCH 23390 (0.5 mg/kg/dose) or sulpiride (80 mg/kg/dose) at 6-h 
intervals and sacrificed 18 h after the final dose. Results are expressed as percent of 
control ± S.E.M. (n= 6-8). Average control values for striatal, nigral, accumbens and 
cortical NPYLI content were 704 ± 81, 552 ± 69, 1618 ± 67 and 898 + 70 pg/mg 
protein, respectively. * p < 0.05 vs. control. 
NPYLI (percent of Control) 
Striatum Nigra Accumbens Cortex 
Vehicle 100 ± 12 100 ± 13 100 + 4 100 + 12 
SKF 38393 97 ± 8 123 ± 7 * 79 ± 4 84 + 7 
Quinpirole * 69 ± 6 110 + 15 * 69 ± 7 78 ± 3 
SCH 23390 102 ± 8 124 ± 6 103 + 3 89 ± 6 
Sulpiride * 59 ± 8 109 + 7 * 66 ± 5 89 ± 7 
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the treatments. The response in the nucleus accumbens was similar to that in the 
striatum. The 0-1 antagonist (SCH 23390) had no significant effect, while quinpirole 
and sulpiride decreased accumbens NPYLI content to 69 and 66% of control, 
respectively. However, in contrast to the striatum, the 0-1 agonist, SKF 38393, 
produced a small but significant decrease (to 79% of control) in accumbens NPYLI 
content. There were no significant effects on cortical NPYLI levels with any of these 
drug administrations. In addition, acute OA agonist and antagonist treatments produced 
no effects on NPYLI content in any of the identified structures (data not shown). 
Response of NPY systems in anterior caudate regions to D-J and 
D-2 receptor stimulation and blockade after various times 
To characterize further the effects of dopaminergic activity on extrapyramidal 
NPY systems, we administered SKF 38393, quinpirole, SCH 23390 or sulpiride as 
described in the previous section and sacrificed the animals 3, 12 or 48 h after the final 
dose (Figure 4.2). The anterior caudate was dissected into three portions (V AC, MAC 
and LAC) from frozen tissue as identified in Figure 4.1 A and B. At the 3-h time point, 
significant alterations in NPY content were found only in the quinpirole group (to 76% 
of control) in the V AC and the sulpiride group (to 65 % of control) in the MAC; in the 
LAC, both quinpirole and sulpiride significantly decreased 3-h NPYLI levels to 59 % and 
55 % of control, respectively. Twelve hours after treatment, quinpirole had comparably 
decreased NPYLI levels in the VAC, MAC and LAC to 47, 65 and 59% of control, 
respectively. Interestingly, sulpiride also decreased NPYLI content in the V AC, MAC 
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Figure 4.2. Effects of multiple doses of dopamine agonists and antagonists on NPY 
systems in discrete regions of the anterior caudate after various times. Rats were 
given five doses of SKF 38393 (20 mg/kg/dose), quinpirole (5 mg/kg/dose), SCH 
23390 (0.5 mg/kg/dose), or sulpiride (80 mg/kg/dose) and sacrificed 3, 12 or 48 h 
after the final dose. Average values for control NPYLI levels are shown in Figure 
4.1. Results are expressed as percent of respective control ± S.E.M. (n=6). 
* p < 0.05 vs. respective controls. 
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and LAC to 71, 35 and 55% of control, respectively, at this time point. However, at 
12 h, regional differences occurred in response to alterations in dopamine D-l receptor 
activity. The D-l agonist, SKF 38393, decreased NPYLI levels in the VAC to 59% of 
control, while the D-l antagonist, SCH 23390, significantly increased NPYLI content in 
the LAC to 124 % of control. No effects in the MAC occurred with either D-l agonist 
or antagonist treatment at 12 h. After 48 h, NPYLI content in all treatment groups in 
the MAC had returned to control levels. Conversely, NPYLI levels in the LAC in SKF 
38393-, SCH 23390-, quinpirole- and sulpiride-treated groups were decreased to 74, 63, 
68 and 61 % of control, respectively. NPYLI content in the VAC remained decreased 
to 57 and 59 % of control in animals receiving SKF 39393 and quinpirole treatments, 
respectively; NPYLI levels in the SCH 23390 treatment group remained unchanged while 
the sulpiride treatment group had returned to control (Figure 4.2 A). 
Response of NPY systems in posterior caudate regions to 
D-J and D-2 receptor stimulation and blockade 
after various times 
To evaluate the effects of dopaminergic activity on NPY systems in the posterior 
caudate, SKF 38393, SCH 23390, quinpirole and sulpiride were administered as 
previously described and the posterior caudate dissected from frozen tissues (MPC, LPC 
and VPC; Figure 4.3 A, B and C, respectively) as identified in Figure 4.1 C and D. 
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Figure 4.3. Effects of multiple doses of dopamine agonists and antagonists on NPY 
systems in discrete regions of the posterior caudate after various times. Animals 
were treated as for Figure 4.2. Average values for control NPYLI levels are shown 
in Figure 4.1. Results are expressed as percent of respective control ± S.E.M. (n=6). 
* p < 0.05 vs. respective control. 
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LPC and VPC to 69, 60 and 63% of control, respectively, while sulpiride had decreased 
NPYLI levels in these structures to 57,48 and 50%, respectively. NPYLI content in the 
VPC was increased by SCH 23390 administration to 158 % of control, while SKF 39393 
had no effect on any of the three structures at this time point. At 12 h after treatment, 
quinpirole had decreased NPYLI levels in the MPC, LPC and VPC to 72, 39, and 40% 
control, respectively; sulpiride had decreased these levels to 55, 30 and 32 % of control, 
respectively. NPYLI content in the VPC remained elevated 12 h after SCH 23390 
administration to 130% of control; in the MPC the SCH 23390 treatment group was 
increased to 122 % of control. In addition, SKF 38393 administration significantly 
reduced NPYLI levels in the VPC to 73 % of control at this time point. After 48 h 
recovery, NPLI levels in all treatment groups in the LPC had returned to control. In the 
MPC, NPYLI levels in the SCH 23390 group had returned to control, but had decreased 
in the SKF 38393 group to 75 % of control. NPYLI content in the MPC remained 
decreased to 57 and 75 % of control, respectively, 48 h after quinpirole and sulpiride 
administration. In the VPC, NPYLI content in all treatment groups had returned to 
control except for the SCH 23390 group which remained increased to 142 % of control 
(Figure 4.3 C). 
Response of NPY systems in anterior and posterior nucleus 
accumbens to D-J and D-2 receptor stimulation and 
blockade after various times 
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To assess the involvement of dopaminergic receptor activity in the regulation of 
limbic NPY systems, we administered SKF 38393, SCH 23390, quinpirole and sulpiride 
as previously described and dissected the nucleus accumbens into anterior (Figure 4.4 A, 
ANA) and posterior (Figure 4.4 B, PNA) portions as identified in Figure 4.1 A and B. 
Three hours after treatment, only SCH 23390 administration significantly altered NPYLI 
content in the ANA (to 140% of control), while SKF 38393, quinpirole and sulpiride all 
decreased NPYLI levels in the PNA to 67, 69 and 63 % of control, respectively. Twelve 
hours after quinpirole treatment, NPYLI content decreased in the ANA and PNA to 56 
and 59% of control, respectively; NPYLI levels decreased in the ANA and PNA to 46 
and 59 % of control, respectively, 12 h after sulpiride treatment. No significant 
differences were seen after either D-1 agonist or antagonist treatment in either region at 
this time point. Unlike most regions of the caudate, by 48 h NPYLI levels in all 
treatment groups in both regions of the nucleus accumbens had returned to control 
(Figure 4.4). 
Response of NPYLI systems in globus pal/idus to D-J and D-2 
receptor stimulation and blockade after various times 
To assess the effect of dopaminergic systems on NPY -containing neurons in the 
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Figure 4.4. Effects of multiple doses of dopamine agonists and antagonists on NPY 
systems in discrete regions of the nucleus accumbens after various times. Rats were 
treated as for Figure 4.2. Average values for control NPYLI levels are shown in 
Figure 4.1. Results are expressed as percent of respective control ± S.E.M. (n=6). 
* p < 0.05 vs. respective control. 
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previously described and dissected the structure from frozen tissue as identified in Fig. 
4-1 D (Figure 4.5). Only quinpirole administration significantly altered globus pallidus 
NPYLI content (51 % of control) 3 h after treatment. Twelve hours after drug 
administration, NPYLI levels in the SKF 38393-, quinpirole- and sulpiride-treatment 
groups were decreased to 57, 59 and 47% of control, respectively, while the SCH 23390 
treatment group remained unchanged. Recovery occurred in all treatment groups by 48 
h except for sulpiride-treated animals. It is of interest to note that control NPYLI levels 
in the globus pallidus are quantitatively more similar to those in the nucleus accumbens 
than in the striatum (Figure 4.1). 
Discussion 
These findings demonstrate the existence of complex interactions between 
dopaminergic and NPY systems in extrapyramidal and limbic structures which are time-
and region-dependent. It is likely that the distinct regional patterns of changes in NPYLI 
content to selective stimulation and blockade of D-l and D-2 receptors reflect changes 
in basal release and synthesis activities and rebound responses. Without additional 
information it is impossible to explain the nature of specific changes in each region 
examined. However, these findings do support general conclusions and have important 
implications for future research in this area. 
The results of this study suggest that regional differences in the regulation of 
neuropeptide Y systems exist in structures frequently analyzed in their entirety (Table 
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Figure 4.5. Effects of multiple doses of dopamine agonists and antagonists 
on NPY systems in the globus pallidus after various time points. Rats were 
treated as described for Figure 4.2. Average value for control NPYLI level 
is shown in Figure 4.1. Results are expressed as percent of respective con-
trol ± S.E.M. (n=6). * p < 0.05 vs. respective control. 
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previous administrations of selective D-l agonists and antagonists, and support our earlier 
findings (Midgley et al., 1989) that striatal NPY systems respond similarly to intermittent 
administration of both D-2 agonists and antagonists. 
Kerkarian et al. (1988) have reported that treatment with the DA D-l antagonist, 
SCH 23390, produces a small but constant increase in the number of NPY -immunoreac-
tive rat striatal neurons. Engber et al. (1992) found that both intermittent and continuous 
administration of the D-l agonist, SKF 38393, produce decreases in rat striatal NPYLI 
content. The present study confirms the work of both investigators, and demonstrates 
that regions within the striatum have distinct responses to D-l stimulation and blockade. 
Since striatal NPY neurons receive synaptic input from tyrosine hydroxylase-positive 
axons (Kubota et al., 1988; Vuillet et al., 1989), and D-l receptor mRNA is expressed 
in a small number of somatostatin-containing neurons (NPY colocalizes with somatostatin 
in the striatum; Le Moine et al., 1991), these changes could be mediated either directly, 
indirectly or both. In addition, our observation of localized striatal responses to D-l 
stimulation and blockade suggests that whole structure analyses may result in a washout 
effect in which regions that remain unchanged in response to drug treatments mask the 
change in responsive areas. This diluting effect may account for our inability to see 
significant changes in response to these drugs in previous studies at the whole structure 
level (Midgley et al., 1989). Regional differences in response to these drugs might 
reflect differences in basal dopaminergic tone; those with high tone (such as the LAC and 
VPC) would be more likely to respond to the antagonist, whereas those with low tone 
(such as the V AC) would more likely respond to the agonist. 
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Interestingly, the 0-1 agonist, SKF 38393, elevated NPYLI levels after three 
hours in the ANA and decreased it in the PNA (Figure 4.4 A and B). However, the 
variability in responses to the 0-1 agonist is not surprising as Salin et ala (1990) found 
that accumbens NPY systems responded to unilateral 6-0HOA lesions in a manner 
opposite that of striatal NPY systems. Furthermore, they reported that apomorphine 
treatment of animals after a 6-0HOA lesion completely reversed ipsilateral anterior but 
not posterior NPYLI decreases. 
In contrast to the opposing effects on striatal NPY systems produced by 0-1 
receptor agonist and antagonist treatments (e.g., Figure 4.3 A and C), intermittent 
administrations of the 0-2 agonist, quinpirole, or the 0-2 antagonist, sulpiride, both 
decreased caudate, pallidal and accumbens NPY levels, although in some regions the 
time course for these effects varied. The apparent contradiction of these results might 
be explained by several mechanisms: 1) The effects of quinpirole and sulpiride could be 
mediated through different populations of neurons, regulated by differential basal 
dopaminergic activity. These effects could be either direct or indirect, but are more 
likely the latter since Le Moine et ala (1991) reported that no DA D-2 receptor mRNA 
exists in striatal NPY -containing neurons. We previously reported that PCP- or MK-801-
induced decreases in striatal NPYLI content are blocked by administration of indirect 
GAB A agonists (Midgley et al., 1992). In addition, Maura et ala (1988) have shown that 
stimulation of 0-2 receptors blocks glutamate release in striatal synaptosomes. 
Therefore, it is possible that the D-2 agonist acts indirectly through glutamate and GABA 
systems to produce its effects on NPYLI levels. Kerkarian-Le Goff et ala (1991) recently 
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reported that striatal choline acetyltransferase-positive neurons receive some nigra! 
dopaminergic input and that these neurons have reciprocal synaptic interactions with 
NPY -containing neurons. Perhaps this system, or a similar one, could be responsible for 
the decreases induced by the D-2 antagonist. 2) The effects of the dopamine D-2 
agonist, quinpirole and the D-2 antagonist, sulpiride, on striatal NPYLI systems could 
actually be mediated principally by two different dopamine receptor SUbtypes. Recently, 
Schwartz et al. (1992) reported that quinpirole has considerably higher affinity for the 
D-3 receptor, while sulpiride has higher affinity for the D-2 receptor; possibly other DA 
receptor subtypes will yet be identified for which the two drugs have differing affinities. 
3) A complex interrelationship between DA postsynaptic receptors and presynaptic 
autoreceptors may account for these complex results. For example, stimulation of D-1 
receptors is necessary for the full expression of postsynaptic effects of dopamine D-2 
agonists (Carlson et al., 1987; Watchel et al., 1989). Thus, the action of quinpirole at 
presynaptic dopamine D-2 autoreceptors might inhibit dopamine release and thereby 
remove the D-1 stimulation necessary for the expression of postsynaptic effects which 
might be expected from D-2 receptor stimulation. In addition, the similar responses by 
striatal NPY systems to D-2 agonists and antagonists could reflect such mechanisms as 
differences in second messenger systems or in synthesis and release of the peptide 
induced by the two drugs. Further studies are necessary to identify the specific 
mechanism(s) involved. 
In addition to quantitative differences in regional NPYLI content observed in 
response to administrations of D-1 and D-2 agonists and antagonists, differences in basal 
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NPYLI levels and the time course of NPYLI changes in response to drug treatment were 
also identified. As described in Figure 4.1, accumbens NPYLI levels are much higher 
than striatal NPYLI levels and posterior striatal levels higher than anterior or very 
posterior striatal levels. In addition, NPYLI levels in the globus pallidus approximated 
those in the nucleus accumbens. These regional differences in basal NPYLI content 
suggest differences in the role or regulation of these regional NPY systems. The 
responses of these regional NPYLI systems to the dopaminergic agonists and antagonists 
also differed in their time courses. For example, SCH 23390 increased NPYLI levels 
early in the VPC but later in the MPC and LAC (Figure 4.3 C and A, Figure 4.2 C); 
SKF 38393 decreased NPYLI levels early in the PNA, but later in the VPC and LAC 
(Figure 4.4 B, Figure 4.3 C and Figure 4.2 C); quinpirole, but not sulpiride, decreased 
NPYLI content in the V AC by 3 h and quinpirole but not sulpiride remained decreased 
at 48 h (Figure 4.2 A) whereas sulpiride, but not quinpirole, decreased NPYLI content 
in the MAC at 3 hr (Figure 4.2 B); and quinpirole but not sulpiride decreased pallidal 
NPYLI content by 3 h while only sulpiride remained decreased by 48 h (Figure 4.5). 
The regional differences in time courses for these drugs could reflect differences in 
kinetics, regional regulation of NPY -containing neurons, or synthesis and release of the 
peptide. 
In summary, the results of this study suggest that intermittent administration of 
a D-1 agonist or antagonist decreased or increased, respectively, NPYLI content in 
selected regions of the rat caudate and globus pallidus at the indicated time points. The 
D-1 agonist increased NPYLI levels in the anterior and decreased them in the posterior 
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nucleus accumbens. The D-1 antagonist had no significant effect in either region of the 
accumbens; however, it did increase NPYLI levels in LAC, MPC and VPC at identified 
time points after treatment. Intermittent administration of either D-2 agonist and 
antagonist reduced NPYLI content in all identified regions of each structure at some time 
point, although the time course and magnitude of effects varied. While the explanation 
for these varied fluctuations is not yet known, they confirm our earlier work (Midgley 
et al., 1989) and that of Kerkarian et al. (1988) and Enger et al. (1992) concerning the 
role of D A receptor subtypes in the regulation of striatal NPY. These data further 
suggest that studies must be carefully designed not to overlook potential regional 
differences which may confound or be diluted out in whole structure analyses. 
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CHAPTER 5 
MECHANISMS OF PCP-INDUCED CHANGES IN 
CENTRAL NEUROPEPTIDE Y SYSTEMS 
Introduction 
Data from the previous chapters suggest that extrapyramidal and lirnbic NPY 
systems are modulated by glutamatergic activity and that the interaction between these 
two systems is mediated, at least in part, by GABAergic mechanisms (Midgley et al., 
1992). However, the previous data do not indicate which GABAergic receptor subtype(s) 
(A or B) may be involved, nor the specific mechanism(s) of action by which PCP is 
affecting central NPY systems. For example, alterations in NPYLI tissue content may 
result from changes in NPY synthesis, release or both. 
Assessment of mechanisms is made difficult by the presence of multiple pop-
ulations of NPY -containing neurons with differential response patterns in discrete brain 
structures (Kubota et al., 1991; Salin et al., 1990; Kuljis and Rakic, 1989; Kerkarian et 
al., 1989). In addition, we have recently completed studies which suggest that the effects 
of PCP and MK-801 on NPY neurons in the anterior caudate and nucleus accumbens, 
and the globus pallidus are very similar; however, in the posterior caudate and nucleus 
accumbens they are dissimilar (data not shown). In this chapter we evaluate the 
mechanisms by which PCP may change NPYLI content by: 1) assessing the effects of 
81 
selective GABAergic agonists on PCP-induced striatal NPYLI changes, 2) evaluating the 
effects of PCP on striatal NPY release and 3) examining the effects of PCP, MK-801, 
quinpirole and sulpiride on striatal, accumbens and cortical NPY messenger ribonucleic 
acid (mRNA). 
Materials and Methods 
Animals and treatments 
Male Sprague-Dawley rats (180-270 g, Simonsen Laboratories, Gilroy, CA) were 
used in all the following experiments and maintained as described in Chapter 2. For 
GABA agonist and mRNA studies, animals received five doses each of PCP (15 
mg/kg/dose), MK-801 (2 or 2.5 mg/kg/dose for agonist and mRNA studies, respectful-
ly), quinpirole (5 mg/kg/dose), sulpiride (80 mg/kg/dose), muscimol (2 mg/kg/dose), 
baclofen (25 mg/kg/dose) or drug combinations at 6-h intervals and were sacrificed 15 
h after the final dose. Agonists were given 20-30 min prior to administration of PCP or 
MK-801. Drug doses, except for MK-801, were calculated for their free forms. All 
drugs were administered intraperitoneally except PCP which was administered 
subcutaneously. All drugs were dissolved in 0.9% saline except for baclofen and 
quinpirole, which were dissolved in 1 % lactate-saline, and sulpiride which was dissolved 
in 2 % lactate + 25 % propylene glycol-saline. 
For NPY release studies, animals were anesthetized with chloral hydrate (375 
mg/kg) and placed in a stereotaxic apparatus. A push-pull cannula was placed 0.5 mm 
anterior to bregma, (-) 2.6 mm lateral to bregma and 5.5 mm ventral from the skull. Rats 
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were allowed to stabilize for 2.5 to 3 h before baselines of NPY release were obtained. 
Samples were collected for 30 min at a flow rate of 13 Jtl/min into 60 1'1 of 0.1 N HCl. 
Artificial cerebral spinal fluid (CSF) (Tatsuoka et al., 1987) consisted of 140 mM NaCl, 
3.5 mM KC1, 1.3 mM CaCI2 , 1.0 mM MgCI2, 5.0 mM HEPES and 0.1 % bovine serum 
albumin (BSA). Striata were perfused with artificial CSF during the stabilization period 
and baseline collections. Subsequently, animals received one dose of PCP (15 mg/kg, 
s.c.) and samples were collected for the remainder of the experiment (usually two more 
collections). 
Dissections 
Animals used for GABA agonist and mRNA studies were sacrificed by 
decapitation 15 h following treatment. Brains were rapidly removed and those used in 
mRNA studies were immediately frozen on dry ice and stored at -80°C until processed. 
Brains from the GABA agonist study had striata excised on ice and brains stored as 
identified in Chapter 2. Animals used in release studies were sacrificed at the end of 
each experiment, their brains removed and cannula placement verified. 
NPY radioimmunoassay 
The antiserum to NPY was prepared as described in Chapter 2. Assays for 
NPYLI were conducted as previously described except in release studies 200 1'1 of 
artificial CSF was substituted for buffer in the standards and samples were run 
individually due to limited NPY concentrations in perfusate. 
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In situ hybridization histochemistry 
A modification of methods previously described by Merchant et ale (1992) was 
used. Briefly, brains were cut into 16-p.M-thick slices, thaw-mounted onto gelatin-
coated slides and stored at -80°C until processed. Slides were warmed to room 
temperature for 10 min, fixed in 4% w/v paraformaldehyde, acetylated with 0.25% v/v 
acetic anhydride in 0.1 M triethanolamine (PH 8.0), dehydrated through a graded series 
of ethanol, delipidated in chloroform, rehydrated to 95% v/v ethanol and air dried. A 
36 base-pair oligonucleotide probe (5' -GGA-GT A-GTA-TCT -GGC-CA TGTC-CTC-TGC 
-TGG-CGC-GCT; Baskin et al., 1990; Higuchi et al., 1988) was terminal deoxyribo-
nucleotidyl transferase (TDT) labelled (Lewis et al., 1986) with US dATP to a specific 
activity of 10.44 p.Ci/pmol. The labelled probe was applied at saturating concentrations 
(2 pmol/ml) in a hybridization solution (10 mM Tris-HCl buffer, pH 8.0, containing 50% 
v/v deionized formamide, 0.3 M NaCl, ImM EDTA, 10% w/v dextran sulfate, 1 x 
Denhardt's solution, 10 mM dithiothreitol, and 0.5 mg/ml yeast tRNA). Sections were 
covered with siliconized coverslips and the slides incubated overnight in a humid 
chamber at 211C (20°C below the calculated melting poinO. The coverslips were 
removed in 1 x SSC (0.15 M NACI + 0.015 M sodium citrate, pH 7.0), and the slides 
washed 3 x 20 min at 6Cfc in 1 x SSC. Slides were then washed in 1 x SSC at room 
temperature for 2 x 60 min., dehydrated through graded alcohols containing 0.6 M 
ammonium acetate, and air dried. 
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Autoradiography 
Following hybridization, slides were apposed to Hyperfilm-max (Amersham) for 
7 days and films developed in Kodak D-19 solution. Slides were then dipped in Kodak 
NTB2 nuclear tract emulsion diluted 1: 1 with 0.6 M ammonium acetate, air dried in the 
dark for 2 h, and exposed for 3 weeks. The emulsion was developed in D-19 diluted 1:1 
with water. Slides were counter-stained in 0.1 % w/v cresyl violet acetate, dehydrated 
and coverslipped with Permount. Brain sections from different treatment groups were 
anatomically matched according to the atlas of Konig and Klippel (1963) under bright 
field prior to evaluation of films and distribution of autoradiographic grains in dark field. 
Statistical analysis 
Data for Figure 5.1 and 5.2 were analyzed as described in Chapter 2. NPYLI 
control value is included in the figure legend. 
Results 
Regulation of striatal NPY systems by GABA A and B receptors 
To examine the influence of selective GABAergic receptors in the regulation of 
striatal NPY systems, we administered the GABA A agonist, muscimol (2 mg/kg/dose, 
Lp.), or the GABA B agonist, baclofen (25 mg/kg/dose, Lp.) alone and in combination 
with PCP (15 mg/kg/dose, s.c.) or MK-801 (2 mg/kg/dose, i.p.). Animals received five 
doses, 6 h apart and were sacrificed 15 h after the final dose. Agonists were adminis-





§ D Bad 
0 i] PCP ... 
-= 1:1 MK-801 0 100 ~ 
c.- IiJ Musc+ PCP 0 
~ IIJ Muse+MK '-' 
-= [! Bad + PCP Q,I 







Figure 5.1. Effects of multiple doses of selective GABA A and B agonists on 
striatal NPYLI content alone and in combination with PCP or MK-801. Rats 
were treated as described in Materials and Methods. Average value for con-
trol NPYLI level was 750 ± 39. Results are expressed as percent of control ± 




PCP and MK-801 decreased striatal NPYLI content, and both the GABA A and B 
agonists completely blocked the PCP- and MK-801-induced changes. We were unable 
to determine clearly the effects of these selective GABAergic drugs on accumbens and 
cortical PCP and MK-801-induced NPYLI decreases because both the GABAergic drugs 
increased NPYLI levels in both tissues in separate experiments (data not shown) 
The role of release in PCP-induced striatal NPYLI changes 
To evaluate the effects of systemic PCP administration on NPY release, we 
administered a single dose of PCP (15 mg/kg, s.c.) to chloral hydrate-anesthetized 
animals implanted with a push-pull cannula as described in Materials and Methods. As 
shown in Figure 5.2, acute PCP administration produced a small (10%) but significant 
increase in the release of striatal NPYLI. 
The role of peptide synthesis in PCP-, MK-80l-, quinpirole- and 
sui pi ride-induced NPYLI changes 
To evaluate whether multiple PCP, MK-801, quinpirole or sulpiride administra-
tions exert their effects on striatal, accumbens and cortical NPY systems through altering 
peptide synthesis, we performed in situ hybridization histochemistry on tissue slices from 
animals treated with these drugs as described in Material and Methods. As shown in 
Figure 5.3 A and B, striatal cell bodies were specifically labelled by the oligonucleotide 
probe for NPY mRNA. Cells positive for NPY message were generally distributed in 
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Figure 5.2. Effect of a single systemic PCP administration (15 mglkg) on 
striatal NPYLI release. Animals were treated as described in Materials and 
Methods. Each data point represents the total of two 30-min collections (n = 




a dispersed pattern throughout the striatum, accumbens and cortex. Using both film 
autoradiography and counting NPY -positive cells on slides we were unable to detect any 
significant overall change in striatal, accumbens or frontal cortex NPY mRNA induced 
by any of the drugs at this time point (data not shown). However, we found significant 
regional induction of NPY mRNA by PCP treatment in two cortical areas at 15 h after 
treatment. The cortical region from anterior caudate to bregma (more posterior 
structures were not examined), which borders the corpus callosum, appeared particularly 
sensitive to the NMDA antagonists. As shown in Figure 5.4 A-C, PCP and MK-801 
treatments significantly increased the presence of NPY -positive neurons in this region to 
577% and 416% of control, respectively. In addition, NPY -positive cells in the cortex 
lateral to the mid-ventral striatum were increased by PCP administration to 257% of 
control (Figure 5.5 A and B). 
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Figure 5.3. Localization of striatal NPY mRNA to cell body with an oligonucleotide 
probe. Animals were treated and tissues processed as described in Materials and 
Methods. Panel A is a light field and panel B a dark field representation. Section was 
taken approximately 1.371-' anterior to bregma in the dorso-medial striatum. 
A 
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Figure 5.4. Effects of multiple systemic PCP and MK-801 administrations on NPY 
mRNA in the cortical-callosal border. Animals were treated and tissues processed as 
described in Material and Methods. Rats were sacrificed 15 h after treatment. These 
representative sections were taken approximately O.87JL anterior to bregma. A. control, 
B. PCP and C. MK-801. 
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Figure 5.5. Effects of multiple systemic PCP administrations on NPY mRNA in the 
lateral cortex. Animals were treated and tissues processed as described in Materials and 
Methods. Rats were sacrificed 15 h after treatment. These representative sections were 




The studies described in previous chapters indicate that central NPY systems are 
regulated by complex interactions between a number of transmitter systems including 
dopamine, glutamate and GABA. The studies described in this chapter confirm our 
previous data and suggest that both peptide synthesis and release may be important 
components of PCP-induced changes in central NPY systems. 
Neuropeptide Y is a relatively large and sticky protein which precludes its 
measurement by microdialysis with existing technology. The only published report to 
date of in vivo NPY release was by Tatsuoka et al. (1987) who observed decreased 
striatal NPYLI release in rats after perfusion with amphetamine (10 mM) using push-pull 
techniques in awake animals. These findings were correlated with increased dopamine 
release, suggesting that dopamine was inhibitory on striatal NPYLI release. However, 
the relevance of these findings must be tempered due to the severe tissue damage and 
stress experienced by conscious animals using this protocol and the extremely high dose 
of amphetamine employed by these researchers. As described in Figure 5.2, we 
observed a small but significant increase in striatal NPYLI release after acute systemic 
PCP administration using push-pull methods in anesthetized animals. Baseline values 
of released NPYLI in our study correlated well with those reported by Tatsuoka et al. 
(1987). However, because of the long time periods required to stabilize the baseline, 
the long half-life of PCP and the high mortality of animals due to the length of the 
procedure, we were unable to follow the time course for PCP-induced NPYLI release 
beyond 2-3 h after drug administration. Although we cannot exclude the possibility that 
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the anesthesia influenced the results obtained with this protocol, based on these and 
previous data, we suggest that PCP is inducing striatal NPY release, likely through its 
action as an NMDA antagonist. 
Lindefors et al. (1990) found that following dopamine deafferentation, the 
numerical density of striatal NPY mRNA producing neurons almost doubled (the opposite 
was true for the fronto-parietal cortex). Data from the mRNA study described in this 
chapter (Figures 5.3-5.5) suggest that PCP treatment increases NPY synthesis in some 
brain regions. However, this was a preliminary experiment with only one animal per 
group and therefore no firm conclusions can be drawn. In addition, the study was 
performed on animals sacrificed at 15 h after the last treatment to coincide with the 
radioimmunoassay data. Merchant et al. (1991) have shown that this is not the time of 
maximal neurotensin mRNA changes after haloperidol treatment; it may also not be the 
time of maximal NPY changes after treatment with PCP, MK-801, quinpirole or 
sulpiride treatments. Clearly a time-course study with adequate numbers of animals is 
the next step in evaluating the effects of these drugs on NPY synthesis. Nevertheless, 
the NPY mRNA changes observed in the two cortical regions (Figures 5.4 and 5.5) were 
pronounced enough to suggest that changes in NPY mRNA do occur in response to PCP 
and MK-801 administration in some structures. 
Administration of the selective direct GABA agonists, muscimol and baclofen, had 
no significant effects by themselves but both drugs completely blocked striatal PCP- and 
MK-801-induced NPYLI changes. Although these data do not clarify the specific role 
of GABA-A and -B receptors (indeed they underscore the complexity of the regulation 
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of NPY systems), they do support our previous hypothesis that GABAergic mechanisms 
are important in the regulation of striatal NPY systems and suggest that both receptor 
types contribute to the PCP-induced effects specifically and NMDA effects in general. 
Based on the data reported here and by others (Le Moine et al., 1991; Kerkarian--
Le Goff et al., 1991; Kubota et al., 1988; Maura et al., 1988; Midgley et al., 1992; 
Vuillet et al., 1989) we propose the following possible synaptic arrangement for striatal 
NPY-containing neurons (Figure 5.6): Neuropeptide Y-containing neurons receive 
direct synaptic input from GABAergic, dopaminergic and cholinergic neurons and 
indirect glutamatergic input mediated through GABAergic neurons. Therefore a decrease 
in glutamatergic activity (as would result from PCP or MK-801 administration in the 
presense of relatively high basal activity) would indirectly increase NPY release and 
decrease its tissue content. This action would thus be compensated for by administration 
of a direct or indirect GABA agonist. Increased NPY synthesis might also be expected 
to occur in response to a glutamatergic antagonist in order to replenish the NPY lost due 
to increased neuronal activity and turnover of the peptide. Administration of a dopamine 
D-2 agonist, according to this scheme, might have an effect similar to a glutamatergic 
antagonist because of its activity at presynaptic D-2 autoreceptors located on glutamate 
terminals (Maura et al . , 1988). The direct dopaminergic input to striatal NPY systems 
is likely mediated through the D-l receptor because no D-2 receptors have been identified 
on striatal NPY-containing neurons (Kubota et al., 1988; Le Moine et al., 1991). 
Excitatory cholinergic neurons synapse on NPY -containing neurons but presumably are 
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Figure 5.6. Proposed synaptic arrangement of GABAergic, 
glutamatergic, dopaminergic and cholinergic neurons in 




under the influence of inhibitory dopaminergic receptors (Kerkarian-Le Goff, 1991) and 
might therefore have low basal activity. Dopaminergic receptors located on striatal 
cholinergic neurons are principally D-2 receptors, with a small number of D-l receptors 
also present (Le Moine et al., 1991). The action of a D-2 antagonist might therefore be 
to remove the dopaminergic inhibition of cholinergic neurons and increase NPY release 
(decreasing NPY tissue levels). Conversely, a scheme where dopaminergic neurons 
synapse on GABAergic interneurons (Le Moine et al., 1991) which then synapse on 
secondary GABAegic neurons (Aoki and Pickel, 1990) that modulate NPY-containing 
neurons would be expected to have a similar effect. Synaptic cartoons such as this are 
speculative and necessarily oversimplified. However, they can be useful tools to assist 
the observer in understanding results and suggesting future paths for research. It is quite 
possible, for example, that GABAergic and glutamatergic neurons are involved in parallel 
processing rather than (or in addition to) in series processing, although this would make 
the D-2 agonist results more difficult to interpret. In addition, the role of the cholinergic 
system in the regulation of striatal NPY - containing neurons is presently unclear. 
In summary, the results of the studies reported in this dissertation suggest that 
striatal, accumbens and cortical NPY systems are regulated principally by glutamatergic, 
dopaminergic and GABAergic activity. They further indicate that glutamatergic 
regulation of NPY -containing neurons in these structures occurs through the NMDA 
receptor and is mediated by GABAergic mechanisms. In addition, these results suggest 
that alterations in both peptide release and synthesis may contribute to the response of 
NPY systems to NMDA antagonists such as PCP. Clearly, more research is needed to 
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determine the complex interaction between glutamatergic, dopaminergic, GABAergic and 
NPY systems, particularly with respect to release and synthesis. One would anticipate 
that such research will lead to a better understanding of the role of neuropeptide Y in 
normal eNS functioning and in pathological conditions. 
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